{
  "schema_version": "0.1.0",
  "case_id": "HR-ML029",
  "record_classification": {
    "synthetic": true,
    "banner": "SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD",
    "real_historical_name": true,
    "public_release_status": "draft"
  },
  "identity": {
    "person_id": "ML029",
    "display_name": "Ella Fitzgerald",
    "aliases": [
      "Ella Jane Fitzgerald",
      "First Lady of Song"
    ],
    "sex": "female",
    "era": "Mid-Late 20th Century",
    "nationality": "American",
    "historical_dates": {
      "birth": {
        "preferred": {
          "iso": "1917-04-25",
          "display": "April 25, 1917",
          "precision": "day",
          "calendar": "gregorian"
        },
        "alternatives": [
          {
            "date": {
              "iso": "1917",
              "display": "1917",
              "precision": "year",
              "calendar": "gregorian"
            },
            "source_ids": [
              "SRC-0008"
            ],
            "resolution_status": "preferred",
            "note": "Roster year agrees with her birth certificate and school records."
          },
          {
            "date": {
              "iso": "1918-04-25",
              "display": "April 25, 1918",
              "precision": "day",
              "calendar": "gregorian"
            },
            "source_ids": [
              "SRC-0001"
            ],
            "resolution_status": "conflicting",
            "note": "Most biographies once gave 1918; her birth certificate and school records show 1917."
          }
        ]
      },
      "death": {
        "preferred": {
          "iso": "1996-06-15",
          "display": "June 15, 1996",
          "precision": "day",
          "calendar": "gregorian"
        },
        "alternatives": [
          {
            "date": {
              "iso": "1996",
              "display": "1996",
              "precision": "year",
              "calendar": "gregorian"
            },
            "source_ids": [
              "SRC-0008"
            ],
            "resolution_status": "preferred",
            "note": "Roster year agrees with the cited sources."
          }
        ]
      }
    },
    "synthetic_identity": {
      "mrn": "HR-ML029-SYN",
      "ssn": "000-29-3640",
      "date_of_birth": "1956-04-25",
      "name_policy": "real_historical_name",
      "fictional_facility": "St. Posthumous Health Center",
      "fictional_primary_clinician": "Odessa Whitlow, MD",
      "fictional_consultant": {
        "name": "Marcus Okafor-Lane, MD",
        "specialty": "Vascular Surgery"
      }
    }
  },
  "historical_timeline": [
    {
      "event_id": "EVT-0001",
      "date": {
        "iso": "1917-04-25",
        "display": "April 25, 1917",
        "precision": "day",
        "calendar": "gregorian"
      },
      "summary": "Born in Newport News, Virginia.",
      "claim_ids": [
        "CLM-0001"
      ]
    },
    {
      "event_id": "EVT-0002",
      "date": {
        "iso": "1932",
        "display": "1932",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "Mother died; placed in an orphan asylum at 15.",
      "claim_ids": [
        "CLM-0002"
      ]
    },
    {
      "event_id": "EVT-0003",
      "date": {
        "iso": "1934",
        "display": "1934",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "Won the Apollo Theater amateur contest.",
      "claim_ids": [
        "CLM-0003"
      ]
    },
    {
      "event_id": "EVT-0004",
      "date": {
        "iso": "1958",
        "display": "1958",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "First Grammy Award.",
      "claim_ids": [
        "CLM-0004"
      ]
    },
    {
      "event_id": "EVT-0005",
      "date": {
        "iso": "1970",
        "display": "1970s",
        "precision": "decade",
        "calendar": "gregorian"
      },
      "summary": "Health problems began; diabetes affected her eyes; cataract surgery, then touring more than 40 weeks a year.",
      "claim_ids": [
        "CLM-0007",
        "CLM-0008"
      ]
    },
    {
      "event_id": "EVT-0006",
      "date": {
        "iso": "1986",
        "display": "1986",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "Intensive care for heart trouble; quintuple-bypass heart surgery.",
      "claim_ids": [
        "CLM-0009"
      ]
    },
    {
      "event_id": "EVT-0007",
      "date": {
        "iso": "1989",
        "display": "1989",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "Spoke of missing the road during her convalescence.",
      "claim_ids": [
        "CLM-0013"
      ]
    },
    {
      "event_id": "EVT-0008",
      "date": {
        "iso": "1992",
        "display": "1992",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "National Medal of Freedom.",
      "claim_ids": [
        "CLM-0005"
      ]
    },
    {
      "event_id": "EVT-0009",
      "date": {
        "iso": "1993",
        "display": "1993",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "Both legs amputated below the knee; created her charitable foundation.",
      "claim_ids": [
        "CLM-0010",
        "CLM-0011",
        "CLM-0012"
      ]
    },
    {
      "event_id": "EVT-0010",
      "date": {
        "iso": "1996-06-15",
        "display": "June 15, 1996",
        "precision": "day",
        "calendar": "gregorian"
      },
      "summary": "Died at home in Beverly Hills.",
      "claim_ids": [
        "CLM-0014"
      ]
    }
  ],
  "claims": [
    {
      "claim_id": "CLM-0001",
      "statement": "Ella Jane Fitzgerald was born on April 25, 1917, in Newport News, Virginia, to Temperance and William Fitzgerald. Most biographies gave 1918, but her birth certificate and school records show 1917.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "source_links": [
        {
          "source_id": "SRC-0002",
          "relationship": "supports",
          "locator": "1917 timeline entry"
        },
        {
          "source_id": "SRC-0001",
          "relationship": "supports",
          "locator": "birth certificate and school records"
        },
        {
          "source_id": "SRC-0008",
          "relationship": "context",
          "locator": "roster birth year 1917"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0002",
      "statement": "In 1932 her mother died suddenly of a heart attack; orphaned at 15, she was placed in the Colored Orphan Asylum in Riverdale, New York.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "Family history from the cited source; age at death not given.",
      "source_links": [
        {
          "source_id": "SRC-0002",
          "relationship": "supports",
          "locator": "1932 timeline entry"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0003",
      "statement": "In 1934 she won an amateur contest at the Apollo Theater in Harlem, which brought her to the attention of the drummer and bandleader Chick Webb; she made her first recording with his band in 1935, and her 1938 swing version of the nursery rhyme \"A-Tisket, A-Tasket\" became her first hit.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "Her life as a performing singer anchors the modern social history.",
      "source_links": [
        {
          "source_id": "SRC-0001",
          "relationship": "supports",
          "locator": "1934 Apollo amateur contest; Chick Webb"
        },
        {
          "source_id": "SRC-0002",
          "relationship": "supports",
          "locator": "1935 and 1938 timeline entries"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0004",
      "statement": "She won the Grammy Award for Best Jazz Individual Performance in 1958 for Ella Fitzgerald Sings the Duke Ellington Song Book, and received the Kennedy Center award for lifetime achievement in 1979. She was known as America's first lady of song.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "Achievement and identity, recorded as strengths.",
      "source_links": [
        {
          "source_id": "SRC-0002",
          "relationship": "supports",
          "locator": "1958 and 1979 timeline entries"
        },
        {
          "source_id": "SRC-0004",
          "relationship": "supports",
          "locator": "America's first lady of song"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0005",
      "statement": "She was awarded the National Medal of Freedom in 1992.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "After the index date.",
      "source_links": [
        {
          "source_id": "SRC-0002",
          "relationship": "supports",
          "locator": "1992 timeline entry"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0007",
      "statement": "She began to have health problems during the 1970s; she had diabetes, which caused problems with her eyes.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "The anchor for the modern diabetic retinopathy. The type of diabetes and its treatment were not made public.",
      "source_links": [
        {
          "source_id": "SRC-0004",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0008",
      "statement": "In the 1970s, after cataract surgery, she returned to touring more than 40 weeks a year.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "The anchor for the lens implants in the modern eye examination and for her touring life.",
      "source_links": [
        {
          "source_id": "SRC-0003",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0009",
      "statement": "In 1986 she was admitted to intensive care for heart trouble and underwent quintuple-bypass heart surgery; the following year she was back onstage.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "The anchor for the modern coronary artery disease after bypass surgery the year before the index visit.",
      "source_links": [
        {
          "source_id": "SRC-0002",
          "relationship": "supports",
          "locator": "1986: admitted to intensive care for heart trouble"
        },
        {
          "source_id": "SRC-0003",
          "relationship": "supports",
          "locator": "quintuple-bypass heart surgery; back onstage the following year"
        },
        {
          "source_id": "SRC-0004",
          "relationship": "supports",
          "locator": "a heart operation in 1986"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0010",
      "statement": "She had been suffering from diabetes and its circulatory system complications for many years before her death.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "The anchor for the modern peripheral artery disease. Reported at her death; no fetched source dates the start of the circulatory complications.",
      "source_links": [
        {
          "source_id": "SRC-0001",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0011",
      "statement": "In 1993 both of her legs were amputated below the knees because of complications of diabetes.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "After the index date; history only. The modern episode does not stage or predict this outcome.",
      "source_links": [
        {
          "source_id": "SRC-0001",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0003",
          "relationship": "supports",
          "locator": "due to complications from diabetes"
        },
        {
          "source_id": "SRC-0004",
          "relationship": "supports",
          "locator": "the effects of diabetes led to operations to remove both her legs"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0012",
      "statement": "In 1993 she created and funded the Ella Fitzgerald Charitable Foundation, whose areas of interest include medical care and research with an emphasis on diabetes, vision problems, and heart disease.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "After the index date; recorded as a strength and as the conditions she chose to name.",
      "source_links": [
        {
          "source_id": "SRC-0005",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0013",
      "statement": "In 1989, asked how she spent her convalescence, she said: \"Staying home and being bored. I miss the road. I miss going overseas.\"",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "Her own public words, after the index date; they show what performing and travel meant to her.",
      "source_links": [
        {
          "source_id": "SRC-0003",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0014",
      "statement": "She died at home in Beverly Hills, California, on June 15, 1996, at 79. The exact cause of death was not released; one public timeline attributes it to complications of diabetes.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "History only; recorded in one sentence.",
      "source_links": [
        {
          "source_id": "SRC-0001",
          "relationship": "supports",
          "locator": "died Saturday at home in Beverly Hills"
        },
        {
          "source_id": "SRC-0003",
          "relationship": "supports",
          "locator": "the exact cause of death was not released"
        },
        {
          "source_id": "SRC-0002",
          "relationship": "supports",
          "locator": "1996 timeline entry"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    }
  ],
  "sources": [
    {
      "source_id": "SRC-0001",
      "title": "'The Greatest': Ella Fitzgerald dies; singer expanded boundaries of jazz with warm sound, acrobatic style",
      "publisher": "The Spokesman-Review (wire reports)",
      "url": "https://www.spokesman.com/stories/1996/jun/16/the-greatest-ella-fitzgerald-dies-singer-expanded/",
      "source_type": "other",
      "published": "1996-06-16",
      "accessed": "2026-11-04",
      "rights_note": "Newspaper obituary from wire reports; facts used with citation."
    },
    {
      "source_id": "SRC-0002",
      "title": "Ella Fitzgerald: career timeline",
      "publisher": "American Masters, PBS (WNET)",
      "url": "https://www.pbs.org/wnet/americanmasters/ella-fitzgerald-career-timeline/591/",
      "source_type": "biography",
      "published": null,
      "accessed": "2026-11-04",
      "rights_note": "Public television biography timeline; facts used with citation."
    },
    {
      "source_id": "SRC-0003",
      "title": "Scat lady",
      "publisher": "Newsweek",
      "url": "https://www.newsweek.com/scat-lady-178732",
      "source_type": "other",
      "published": "1996-06",
      "accessed": "2026-11-04",
      "rights_note": "News magazine obituary; short quotations used with citation."
    },
    {
      "source_id": "SRC-0004",
      "title": "Ella Fitzgerald, 1917-1996: America's First Lady of Song",
      "publisher": "VOA Learning English (Voice of America)",
      "url": "https://learningenglish.voanews.com/a/ella-fitzgerald-1917-1996-americas-first-lady-of-song-97708054/114092.html",
      "source_type": "government",
      "published": null,
      "accessed": "2026-11-04",
      "rights_note": "U.S. government broadcaster biography; facts used with citation."
    },
    {
      "source_id": "SRC-0005",
      "title": "The Ella Fitzgerald Charitable Foundation",
      "publisher": "The Ella Fitzgerald Charitable Foundation (official site)",
      "url": "https://www.ellafitzgerald.com/foundation",
      "source_type": "primary",
      "published": null,
      "accessed": "2026-11-04",
      "rights_note": "Official foundation page; used only for CLM-0012."
    },
    {
      "source_id": "SRC-0008",
      "title": "HISTMED Master Roster v3",
      "publisher": "The Human Record project",
      "url": "https://humanrecord.example.org/internal/HISTMED_Master_Roster_v3.xlsx",
      "source_type": "other",
      "published": "2026-11-04",
      "accessed": "2026-11-04",
      "rights_note": "Internal source locator; inherited claims remain provisional until corroborated."
    }
  ],
  "synthetic_episode": {
    "calendar_frame": "modern_shifted",
    "index_date": "2026-05-11",
    "index_age": 70,
    "date_shift_policy": "HR-DATE-SHIFT-1",
    "teaching_objective": "Limb-, sight- and heart-protecting primary care for a 70-year-old touring singer with type 2 diabetes, peripheral artery disease with claudication, diabetic macular edema, and coronary bypass surgery the year before: the comprehensive diabetic foot examination (inspection, 10-g monofilament, vibration, pulses) with the ankle- and toe-brachial indices, IWGDF risk grading and a high-risk foot program with podiatry and stage footwear; prompt vascular surgery evaluation, supervised exercise therapy, and a clear plan for revascularization if symptoms limit her life; a high-intensity statin with ezetimibe to an LDL below 55 mg/dL, aspirin with low-dose rivaroxaban, and glucose-lowering medicines with cardiovascular and kidney benefit (empagliflozin, then semaglutide) in place of a sulfonylurea; retinal care with anti-VEGF injections; kidney monitoring; hypoglycemia safety on tour (insulin timing across time zones, a continuous glucose monitor, glucagon, and a show-day plan); and the equity and access steps that make this care reach her, on the ADA Standards of Care 2026, the IWGDF 2023 guidelines, the 2024 ACC/AHA lower extremity PAD guideline, and the CMID diabetes monograph.",
    "visit_schedule": [
      {
        "encounter_id": "ENC-001",
        "date": "2026-05-11",
        "purpose": "New patient visit: diabetes with calf pain on walking, low glucose after late shows, eye and foot examinations, and cardiovascular risk"
      },
      {
        "encounter_id": "ENC-002",
        "date": "2026-05-26",
        "purpose": "Two-week review: glucose and hypoglycemia safety on the new plan, and vascular surgery consultation"
      },
      {
        "encounter_id": "ENC-005",
        "date": "2026-06-15",
        "purpose": "Subsequent annual wellness visit"
      },
      {
        "encounter_id": "ENC-003",
        "date": "2026-08-10",
        "purpose": "Three-month review: A1c, lipids, walking program, eye treatment, and foot care"
      },
      {
        "encounter_id": "ENC-004",
        "date": "2026-10-26",
        "purpose": "Five-and-a-half-month review: A1c, lipids, walking distance, revascularization decision, foot and eye follow-up"
      }
    ]
  },
  "clinical": {
    "problems": [
      {
        "id": "PRB-001",
        "display": "Type 2 diabetes mellitus with peripheral artery disease: cramping in both calves after about one and a half blocks of walking, worse on the right, easing within minutes of rest; no rest pain, wounds, or color change. Resting ankle-brachial index 0.62 right and 0.74 left, toe-brachial index 0.46 and 0.55; dorsalis pedis and posterior tibial pulses absent on the right and faint on the left. A1c 8.6% on metformin, glipizide and glargine, with low glucose readings (to 52 mg/dL) after late performances. Foot: protective sensation intact to the 10-g monofilament at all sites and to vibration; callus under the second metatarsal heads; hammer toes of the second and third toes; no ulcer (IWGDF risk category 2). Synthetic modern episode linked to her documented diabetes and its circulatory complications",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "E11.51",
            "display": "Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic modern diagnosis; the type of diabetes was not made public and is synthetic.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "active"
      },
      {
        "id": "PRB-002",
        "display": "Moderate nonproliferative diabetic retinopathy with center-involving diabetic macular edema in the right eye (best-corrected acuity 64 letters, about 20/50) and moderate nonproliferative retinopathy without macular edema in the left eye (81 letters); lens implants in both eyes from earlier cataract surgery. Synthetic modern episode linked to her documented diabetic eye problems",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "E11.3311",
            "display": "Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0008"
          ],
          "synthetic_reason": "Synthetic modern eye diagnosis on retinal imaging and optical coherence tomography in the clinic; the left eye is described in the display.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "active"
      },
      {
        "id": "PRB-003",
        "display": "Coronary artery disease after five-vessel coronary bypass surgery last year, with an intensive care stay; no angina now; on aspirin, a statin, and metoprolol. Synthetic modern episode linked to her documented heart surgery",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "I25.10",
            "display": "Atherosclerotic heart disease of native coronary artery without angina pectoris",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic modern coding of her documented heart surgery; bypass grafts are described in the display.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "active"
      }
    ],
    "medications": [
      {
        "id": "MED-001",
        "display": "Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "861004",
            "display": "metformin hydrochloride 1000 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 12,
          "period_unit": "h",
          "text": "One tablet by mouth twice daily with breakfast and the evening meal"
        },
        "start_date": "2016-03-01",
        "indication_problem_ids": [
          "PRB-001"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic long-term metformin; the type of diabetes and its real treatment were not made public.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "MED-002",
        "display": "Glipizide 10 mg oral tablet, one tablet by mouth twice daily before meals",
        "status": "completed",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "310488",
            "display": "glipizide 10 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 12,
          "period_unit": "h",
          "text": "One tablet by mouth twice daily before breakfast and the evening meal"
        },
        "start_date": "2021-09-01",
        "end_date": "2026-05-11",
        "indication_problem_ids": [
          "PRB-001"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic sulfonylurea, stopped at intake because of low glucose readings after late performances.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "MED-003",
        "display": "Insulin glargine 100 units/mL pen, 30 units under the skin at bedtime",
        "status": "completed",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "847230",
            "display": "3 ML insulin glargine 100 UNT/ML Pen Injector",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "dose": {
          "value": 30,
          "unit": "[IU]"
        },
        "route": "subcutaneous",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "30 units at bedtime"
        },
        "start_date": "2023-04-01",
        "end_date": "2026-05-11",
        "indication_problem_ids": [
          "PRB-001"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic basal insulin at the dose she was taking before intake.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "MED-004",
        "display": "Insulin glargine 100 units/mL pen, 24 units under the skin each morning",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "847230",
            "display": "3 ML insulin glargine 100 UNT/ML Pen Injector",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "dose": {
          "value": 24,
          "unit": "[IU]"
        },
        "route": "subcutaneous",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "24 units each morning, at the same clock time on tour, with written time-zone adjustments"
        },
        "start_date": "2026-05-11",
        "indication_problem_ids": [
          "PRB-001"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic basal insulin reduced by 20% and moved to the morning to lower the risk of night-time lows after late shows.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "MED-005",
        "display": "Atorvastatin 40 mg oral tablet, one tablet by mouth daily",
        "status": "completed",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "617311",
            "display": "atorvastatin 40 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "One tablet by mouth daily"
        },
        "start_date": "2025-06-02",
        "end_date": "2026-05-11",
        "indication_problem_ids": [
          "PRB-003",
          "PRB-001"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic statin started after bypass surgery; raised at intake.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "MED-006",
        "display": "Atorvastatin 80 mg oral tablet, one tablet by mouth daily",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "259255",
            "display": "atorvastatin 80 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "One tablet by mouth daily"
        },
        "start_date": "2026-05-11",
        "indication_problem_ids": [
          "PRB-003",
          "PRB-001"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic high-intensity statin for coronary and peripheral artery disease.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "MED-007",
        "display": "Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "308416",
            "display": "aspirin 81 MG Delayed Release Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "One tablet by mouth daily"
        },
        "start_date": "2025-06-02",
        "indication_problem_ids": [
          "PRB-003",
          "PRB-001"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic antiplatelet therapy after bypass surgery.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "MED-008",
        "display": "Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "866427",
            "display": "metoprolol succinate 25 MG 24HR Extended Release Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "One tablet by mouth daily"
        },
        "start_date": "2025-06-02",
        "indication_problem_ids": [
          "PRB-003"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic beta-blocker after bypass surgery; it can blunt the warning signs of a low glucose.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "MED-009",
        "display": "Empagliflozin 10 mg oral tablet, one tablet by mouth each morning",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "1545658",
            "display": "empagliflozin 10 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "One tablet by mouth each morning; hold on days she cannot eat or drink normally and before surgery"
        },
        "start_date": "2026-05-11",
        "indication_problem_ids": [
          "PRB-001",
          "PRB-003"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010",
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic SGLT2 inhibitor with proven cardiovascular benefit, chosen with her coronary disease; kidney protection as well.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "MED-010",
        "display": "Glucagon 3 mg nasal powder, one spray into one nostril for a severe low glucose",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "2180666",
            "display": "glucagon 3 MG Nasal Powder",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "nasal",
        "frequency": {
          "period": 15,
          "period_unit": "min",
          "text": "One spray into one nostril if she cannot safely swallow during a low glucose; may repeat once after 15 minutes with a new device; call 911"
        },
        "start_date": "2026-05-11",
        "indication_problem_ids": [
          "PRB-001"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic rescue glucagon for a person on insulin, carried on tour.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "MED-011",
        "display": "Rivaroxaban 2.5 mg oral tablet, one tablet by mouth twice daily with aspirin 81 mg",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "2059015",
            "display": "rivaroxaban 2.5 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 12,
          "period_unit": "h",
          "text": "One tablet by mouth twice daily, with aspirin 81 mg once daily"
        },
        "start_date": "2026-05-26",
        "indication_problem_ids": [
          "PRB-001",
          "PRB-003"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic low-dose rivaroxaban with aspirin for symptomatic peripheral artery disease, on the vascular surgeon's advice.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "MED-012",
        "display": "Semaglutide 0.25 mg under the skin once weekly for four weeks",
        "status": "completed",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "2619152",
            "display": "0.25 MG, 0.5 MG Dose 3 ML semaglutide 0.68 MG/ML Pen Injector",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "dose": {
          "value": 0.25,
          "unit": "mg"
        },
        "route": "subcutaneous",
        "frequency": {
          "period": 1,
          "period_unit": "wk",
          "text": "0.25 mg once weekly on the same day each week for four weeks"
        },
        "start_date": "2026-08-10",
        "end_date": "2026-09-07",
        "indication_problem_ids": [
          "PRB-001",
          "PRB-003"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic GLP-1 receptor agonist started for cardiovascular benefit, glucose, and walking distance in peripheral artery disease.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "MED-013",
        "display": "Semaglutide 0.5 mg under the skin once weekly",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "2619152",
            "display": "0.25 MG, 0.5 MG Dose 3 ML semaglutide 0.68 MG/ML Pen Injector",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "dose": {
          "value": 0.5,
          "unit": "mg"
        },
        "route": "subcutaneous",
        "frequency": {
          "period": 1,
          "period_unit": "wk",
          "text": "0.5 mg once weekly on the same day each week"
        },
        "start_date": "2026-09-07",
        "indication_problem_ids": [
          "PRB-001",
          "PRB-003"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic maintenance dose after four weeks at 0.25 mg.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "MED-014",
        "display": "Ezetimibe 10 mg oral tablet, one tablet by mouth daily",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "349556",
            "display": "ezetimibe 10 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "One tablet by mouth daily"
        },
        "start_date": "2026-08-10",
        "indication_problem_ids": [
          "PRB-003",
          "PRB-001"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic ezetimibe added because LDL was 64 mg/dL on atorvastatin 80 mg, above the goal below 55 mg/dL.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      }
    ],
    "allergies": [
      {
        "id": "ALG-001",
        "display": "No known allergy",
        "status": "active",
        "assertion": "no_known_allergy",
        "substance": {
          "system": "http://snomed.info/sct",
          "code": "716186003",
          "display": "No known allergy"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic allergy assertion for EHR completeness; not a historical assertion.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      }
    ],
    "observations": [
      {
        "id": "OBS-A1C-V1",
        "display": "Hemoglobin A1c/Hemoglobin.total in Blood",
        "label": "Hemoglobin A1c",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-05-11",
        "value": 8.6,
        "unit": "%",
        "reference_range": {
          "high": 5.6,
          "text": "Below 5.7% is normal; her individualized goal is below 7.5%"
        },
        "interpretation": "H",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "4548-4",
            "display": "Hemoglobin A1c/Hemoglobin.total in Blood",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic A1c above her goal, with low glucose readings after late shows.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-NA-V1",
        "display": "Sodium [Moles/volume] in Serum or Plasma",
        "label": "Sodium",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-05-11",
        "value": 139,
        "unit": "mmol/L",
        "reference_range": {
          "low": 135,
          "high": 145
        },
        "interpretation": "N",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2951-2",
            "display": "Sodium [Moles/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic metabolic panel; kidney function normal for her age.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-K-V1",
        "display": "Potassium [Moles/volume] in Serum or Plasma",
        "label": "Potassium",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-05-11",
        "value": 4.4,
        "unit": "mmol/L",
        "reference_range": {
          "low": 3.5,
          "high": 5.1
        },
        "interpretation": "N",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2823-3",
            "display": "Potassium [Moles/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic metabolic panel; kidney function normal for her age.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-CR-V1",
        "display": "Creatinine [Mass/volume] in Serum or Plasma",
        "label": "Creatinine",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-05-11",
        "value": 0.92,
        "unit": "mg/dL",
        "reference_range": {
          "low": 0.59,
          "high": 1.04
        },
        "interpretation": "N",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2160-0",
            "display": "Creatinine [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic metabolic panel; kidney function normal for her age.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-EGFR-V1",
        "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
        "label": "eGFR",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-05-11",
        "value": 67,
        "unit": "mL/min/{1.73_m2}",
        "reference_range": {
          "low": 60
        },
        "interpretation": "N",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "98979-8",
            "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic metabolic panel; kidney function normal for her age.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-GLU-V1",
        "display": "Glucose [Mass/volume] in Serum or Plasma",
        "label": "Glucose",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-05-11",
        "value": 168,
        "unit": "mg/dL",
        "reference_range": {
          "low": 70,
          "high": 99
        },
        "interpretation": "H",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2345-7",
            "display": "Glucose [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic metabolic panel; kidney function normal for her age.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-UACR-V1",
        "display": "Albumin/Creatinine [Mass Ratio] in Urine",
        "label": "Urine albumin-creatinine ratio",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-05-11",
        "value": 18,
        "unit": "mg/g",
        "reference_range": {
          "high": 30
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "9318-7",
            "display": "Albumin/Creatinine [Mass Ratio] in Urine",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic urine albumin-creatinine ratio; normal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-CHOL-V1",
        "display": "Cholesterol [Mass/volume] in Serum or Plasma",
        "label": "Total cholesterol",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-05-11",
        "value": 164,
        "unit": "mg/dL",
        "reference_range": {
          "high": 199
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2093-3",
            "display": "Cholesterol [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic lipid panel on atorvastatin 40 mg, above her goal after bypass surgery.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-LDL-V1",
        "display": "Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation",
        "label": "LDL cholesterol",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-05-11",
        "value": 92,
        "unit": "mg/dL",
        "reference_range": {
          "high": 99,
          "text": "Her goal with coronary and peripheral artery disease is below 55 mg/dL"
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "13457-7",
            "display": "Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic lipid panel on atorvastatin 40 mg, above her goal after bypass surgery.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-HDL-V1",
        "display": "Cholesterol in HDL [Mass/volume] in Serum or Plasma",
        "label": "HDL cholesterol",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-05-11",
        "value": 44,
        "unit": "mg/dL",
        "reference_range": {
          "low": 50
        },
        "interpretation": "L",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2085-9",
            "display": "Cholesterol in HDL [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic lipid panel on atorvastatin 40 mg, above her goal after bypass surgery.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-TG-V1",
        "display": "Triglyceride [Mass/volume] in Serum or Plasma",
        "label": "Triglycerides",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-05-11",
        "value": 140,
        "unit": "mg/dL",
        "reference_range": {
          "high": 149
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2571-8",
            "display": "Triglyceride [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic lipid panel on atorvastatin 40 mg, above her goal after bypass surgery.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALT-V1",
        "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "ALT",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-05-11",
        "value": 22,
        "unit": "U/L",
        "reference_range": {
          "low": 7,
          "high": 35
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1742-6",
            "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic liver tests before the statin dose is raised.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-AST-V1",
        "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "AST",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-05-11",
        "value": 24,
        "unit": "U/L",
        "reference_range": {
          "low": 10,
          "high": 35
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1920-8",
            "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic liver tests before the statin dose is raised.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-HGB-V1",
        "display": "Hemoglobin [Mass/volume] in Blood",
        "label": "Hemoglobin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-05-11",
        "value": 12.4,
        "unit": "g/dL",
        "reference_range": {
          "low": 11.6,
          "high": 15.0
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "718-7",
            "display": "Hemoglobin [Mass/volume] in Blood",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic hemoglobin.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-B12-V1",
        "display": "Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma",
        "label": "Vitamin B12",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-05-11",
        "value": 386,
        "unit": "pg/mL",
        "reference_range": {
          "low": 232,
          "high": 1245
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2132-9",
            "display": "Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic vitamin B12 on long-term metformin.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-ABIR-V1",
        "display": "Ankle-brachial index",
        "label": "Ankle-brachial index, right",
        "status": "final",
        "category": "imaging",
        "effective_date": "2026-05-11",
        "value": 0.62,
        "unit": "{ratio}",
        "reference_range": {
          "low": 1.0,
          "high": 1.4,
          "text": "1.00 to 1.40 normal; 0.91 to 0.99 borderline; 0.90 or below abnormal"
        },
        "interpretation": "L",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "77194-9",
            "display": "Ankle-brachial index",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic resting ankle-brachial index: moderate peripheral artery disease on the right.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-ABIL-V1",
        "display": "Ankle-brachial index",
        "label": "Ankle-brachial index, left",
        "status": "final",
        "category": "imaging",
        "effective_date": "2026-05-11",
        "value": 0.74,
        "unit": "{ratio}",
        "reference_range": {
          "low": 1.0,
          "high": 1.4,
          "text": "1.00 to 1.40 normal; 0.91 to 0.99 borderline; 0.90 or below abnormal"
        },
        "interpretation": "L",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "77194-9",
            "display": "Ankle-brachial index",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic resting ankle-brachial index: peripheral artery disease on the left.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-TBIR-V1",
        "display": "Toe brachial index - right",
        "label": "Toe-brachial index, right",
        "status": "final",
        "category": "imaging",
        "effective_date": "2026-05-11",
        "value": 0.46,
        "unit": "{ratio}",
        "reference_range": {
          "low": 0.7,
          "text": "Above 0.70 normal"
        },
        "interpretation": "L",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "77618-7",
            "display": "Toe brachial index - right",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic toe-brachial index, measured because arterial calcification in diabetes can make the ankle index read falsely high.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-TBIL-V1",
        "display": "Toe brachial index - left",
        "label": "Toe-brachial index, left",
        "status": "final",
        "category": "imaging",
        "effective_date": "2026-05-11",
        "value": 0.55,
        "unit": "{ratio}",
        "reference_range": {
          "low": 0.7,
          "text": "Above 0.70 normal"
        },
        "interpretation": "L",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "77617-9",
            "display": "Toe brachial index - left",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic toe-brachial index.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-VAR-V1",
        "display": "Visual acuity best corrected Right eye by ETDRS eye chart",
        "label": "Best-corrected visual acuity, right eye (ETDRS letters)",
        "status": "final",
        "category": "imaging",
        "effective_date": "2026-05-11",
        "value": 64,
        "unit": "{letters}",
        "reference_range": {
          "low": 80,
          "text": "85 letters is about 20/20; 80 about 20/25; 65 about 20/50"
        },
        "interpretation": "L",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "79876-9",
            "display": "Visual acuity best corrected Right eye by ETDRS eye chart",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0008"
          ],
          "synthetic_reason": "Synthetic best-corrected acuity, right eye, reduced with macular edema; not a measurement from her lifetime.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-VAL-V1",
        "display": "Visual acuity best corrected Left eye by ETDRS eye chart",
        "label": "Best-corrected visual acuity, left eye (ETDRS letters)",
        "status": "final",
        "category": "imaging",
        "effective_date": "2026-05-11",
        "value": 81,
        "unit": "{letters}",
        "reference_range": {
          "low": 80,
          "text": "85 letters is about 20/20; 80 about 20/25; 65 about 20/50"
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "79877-7",
            "display": "Visual acuity best corrected Left eye by ETDRS eye chart",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0008"
          ],
          "synthetic_reason": "Synthetic best-corrected acuity, left eye.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-PHQ2-V5",
        "display": "Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]",
        "label": "PHQ-2",
        "status": "final",
        "effective_date": "2026-06-15",
        "value": 0,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "55758-7",
            "display": "Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic negative depression screen at the annual wellness visit.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-MINICOG-V5",
        "display": "Total score [Mini-Cog]",
        "label": "Mini-Cog",
        "status": "final",
        "effective_date": "2026-06-15",
        "value": 5,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "72233-0",
            "display": "Total score [Mini-Cog]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic cognitive screen, normal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-AUDITC-V5",
        "display": "Total score [AUDIT-C]",
        "label": "AUDIT-C",
        "status": "final",
        "effective_date": "2026-06-15",
        "value": 1,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "75626-2",
            "display": "Total score [AUDIT-C]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic alcohol screen, below the risk threshold.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-A1C-V3",
        "display": "Hemoglobin A1c/Hemoglobin.total in Blood",
        "label": "Hemoglobin A1c",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-10",
        "value": 7.6,
        "unit": "%",
        "reference_range": {
          "high": 5.6,
          "text": "Below 5.7% is normal; her individualized goal is below 7.5%"
        },
        "interpretation": "H",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "4548-4",
            "display": "Hemoglobin A1c/Hemoglobin.total in Blood",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic A1c three months after the plan changed.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-NA-V3",
        "display": "Sodium [Moles/volume] in Serum or Plasma",
        "label": "Sodium",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-10",
        "value": 140,
        "unit": "mmol/L",
        "reference_range": {
          "low": 135,
          "high": 145
        },
        "interpretation": "N",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2951-2",
            "display": "Sodium [Moles/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic metabolic panel three months after starting empagliflozin; the small creatinine rise is the expected early effect.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-K-V3",
        "display": "Potassium [Moles/volume] in Serum or Plasma",
        "label": "Potassium",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-10",
        "value": 4.6,
        "unit": "mmol/L",
        "reference_range": {
          "low": 3.5,
          "high": 5.1
        },
        "interpretation": "N",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2823-3",
            "display": "Potassium [Moles/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic metabolic panel three months after starting empagliflozin; the small creatinine rise is the expected early effect.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-CR-V3",
        "display": "Creatinine [Mass/volume] in Serum or Plasma",
        "label": "Creatinine",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-10",
        "value": 0.96,
        "unit": "mg/dL",
        "reference_range": {
          "low": 0.59,
          "high": 1.04
        },
        "interpretation": "N",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2160-0",
            "display": "Creatinine [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic metabolic panel three months after starting empagliflozin; the small creatinine rise is the expected early effect.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-EGFR-V3",
        "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
        "label": "eGFR",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-10",
        "value": 64,
        "unit": "mL/min/{1.73_m2}",
        "reference_range": {
          "low": 60
        },
        "interpretation": "N",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "98979-8",
            "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic metabolic panel three months after starting empagliflozin; the small creatinine rise is the expected early effect.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-CHOL-V3",
        "display": "Cholesterol [Mass/volume] in Serum or Plasma",
        "label": "Total cholesterol",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-10",
        "value": 128,
        "unit": "mg/dL",
        "reference_range": {
          "high": 199
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2093-3",
            "display": "Cholesterol [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic lipid panel thirteen weeks after the statin was raised to 80 mg.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-LDL-V3",
        "display": "Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation",
        "label": "LDL cholesterol",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-10",
        "value": 64,
        "unit": "mg/dL",
        "reference_range": {
          "high": 99,
          "text": "Her goal with coronary and peripheral artery disease is below 55 mg/dL"
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "13457-7",
            "display": "Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic lipid panel thirteen weeks after the statin was raised to 80 mg.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-HDL-V3",
        "display": "Cholesterol in HDL [Mass/volume] in Serum or Plasma",
        "label": "HDL cholesterol",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-10",
        "value": 46,
        "unit": "mg/dL",
        "reference_range": {
          "low": 50
        },
        "interpretation": "L",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2085-9",
            "display": "Cholesterol in HDL [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic lipid panel thirteen weeks after the statin was raised to 80 mg.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-TG-V3",
        "display": "Triglyceride [Mass/volume] in Serum or Plasma",
        "label": "Triglycerides",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-10",
        "value": 112,
        "unit": "mg/dL",
        "reference_range": {
          "high": 149
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2571-8",
            "display": "Triglyceride [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic lipid panel thirteen weeks after the statin was raised to 80 mg.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-VAR-V3",
        "display": "Visual acuity best corrected Right eye by ETDRS eye chart",
        "label": "Best-corrected visual acuity, right eye (ETDRS letters)",
        "status": "final",
        "category": "imaging",
        "effective_date": "2026-08-10",
        "value": 71,
        "unit": "{letters}",
        "reference_range": {
          "low": 80,
          "text": "85 letters is about 20/20; 80 about 20/25; 65 about 20/50"
        },
        "interpretation": "L",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "79876-9",
            "display": "Visual acuity best corrected Right eye by ETDRS eye chart",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0008"
          ],
          "synthetic_reason": "Synthetic acuity, right eye, after three anti-VEGF injections.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-VAL-V3",
        "display": "Visual acuity best corrected Left eye by ETDRS eye chart",
        "label": "Best-corrected visual acuity, left eye (ETDRS letters)",
        "status": "final",
        "category": "imaging",
        "effective_date": "2026-08-10",
        "value": 81,
        "unit": "{letters}",
        "reference_range": {
          "low": 80,
          "text": "85 letters is about 20/20; 80 about 20/25; 65 about 20/50"
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "79877-7",
            "display": "Visual acuity best corrected Left eye by ETDRS eye chart",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0008"
          ],
          "synthetic_reason": "Synthetic acuity, left eye.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-A1C-V4",
        "display": "Hemoglobin A1c/Hemoglobin.total in Blood",
        "label": "Hemoglobin A1c",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-26",
        "value": 7.1,
        "unit": "%",
        "reference_range": {
          "high": 5.6,
          "text": "Below 5.7% is normal; her individualized goal is below 7.5%"
        },
        "interpretation": "H",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "4548-4",
            "display": "Hemoglobin A1c/Hemoglobin.total in Blood",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic A1c on semaglutide 0.5 mg weekly.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-NA-V4",
        "display": "Sodium [Moles/volume] in Serum or Plasma",
        "label": "Sodium",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-26",
        "value": 139,
        "unit": "mmol/L",
        "reference_range": {
          "low": 135,
          "high": 145
        },
        "interpretation": "N",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2951-2",
            "display": "Sodium [Moles/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic metabolic panel.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-K-V4",
        "display": "Potassium [Moles/volume] in Serum or Plasma",
        "label": "Potassium",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-26",
        "value": 4.5,
        "unit": "mmol/L",
        "reference_range": {
          "low": 3.5,
          "high": 5.1
        },
        "interpretation": "N",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2823-3",
            "display": "Potassium [Moles/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic metabolic panel.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-CR-V4",
        "display": "Creatinine [Mass/volume] in Serum or Plasma",
        "label": "Creatinine",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-26",
        "value": 0.94,
        "unit": "mg/dL",
        "reference_range": {
          "low": 0.59,
          "high": 1.04
        },
        "interpretation": "N",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2160-0",
            "display": "Creatinine [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic metabolic panel.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-EGFR-V4",
        "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
        "label": "eGFR",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-26",
        "value": 65,
        "unit": "mL/min/{1.73_m2}",
        "reference_range": {
          "low": 60
        },
        "interpretation": "N",
        "panel": {
          "code": "51990-0",
          "display": "Basic metabolic panel - Blood"
        },
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "98979-8",
            "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic metabolic panel.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-CHOL-V4",
        "display": "Cholesterol [Mass/volume] in Serum or Plasma",
        "label": "Total cholesterol",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-26",
        "value": 114,
        "unit": "mg/dL",
        "reference_range": {
          "high": 199
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2093-3",
            "display": "Cholesterol [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic lipid panel eleven weeks after ezetimibe was added.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-LDL-V4",
        "display": "Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation",
        "label": "LDL cholesterol",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-26",
        "value": 48,
        "unit": "mg/dL",
        "reference_range": {
          "high": 99,
          "text": "Her goal with coronary and peripheral artery disease is below 55 mg/dL"
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "13457-7",
            "display": "Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic lipid panel eleven weeks after ezetimibe was added.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-HDL-V4",
        "display": "Cholesterol in HDL [Mass/volume] in Serum or Plasma",
        "label": "HDL cholesterol",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-26",
        "value": 47,
        "unit": "mg/dL",
        "reference_range": {
          "low": 50
        },
        "interpretation": "L",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2085-9",
            "display": "Cholesterol in HDL [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic lipid panel eleven weeks after ezetimibe was added.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-TG-V4",
        "display": "Triglyceride [Mass/volume] in Serum or Plasma",
        "label": "Triglycerides",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-26",
        "value": 96,
        "unit": "mg/dL",
        "reference_range": {
          "high": 149
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2571-8",
            "display": "Triglyceride [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic lipid panel eleven weeks after ezetimibe was added.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-VAR-V4",
        "display": "Visual acuity best corrected Right eye by ETDRS eye chart",
        "label": "Best-corrected visual acuity, right eye (ETDRS letters)",
        "status": "final",
        "category": "imaging",
        "effective_date": "2026-10-26",
        "value": 75,
        "unit": "{letters}",
        "reference_range": {
          "low": 80,
          "text": "85 letters is about 20/20; 80 about 20/25; 65 about 20/50"
        },
        "interpretation": "L",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "79876-9",
            "display": "Visual acuity best corrected Right eye by ETDRS eye chart",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0008"
          ],
          "synthetic_reason": "Synthetic acuity, right eye, after five anti-VEGF injections.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "OBS-VAL-V4",
        "display": "Visual acuity best corrected Left eye by ETDRS eye chart",
        "label": "Best-corrected visual acuity, left eye (ETDRS letters)",
        "status": "final",
        "category": "imaging",
        "effective_date": "2026-10-26",
        "value": 81,
        "unit": "{letters}",
        "reference_range": {
          "low": 80,
          "text": "85 letters is about 20/20; 80 about 20/25; 65 about 20/50"
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "79877-7",
            "display": "Visual acuity best corrected Left eye by ETDRS eye chart",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0008"
          ],
          "synthetic_reason": "Synthetic acuity, left eye.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      }
    ],
    "procedures": [
      {
        "id": "PROC-003",
        "display": "Advance care planning conversation, about 18 minutes",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "713603004",
            "display": "Advance care planning",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "period": {
          "start": "2026-06-15",
          "end": "2026-06-15"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic voluntary advance care planning; records only her own general preferences.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "PROC-001",
        "display": "Right-eye intravitreal anti-VEGF injection by the retina clinic (dose 1 of 3 monthly loading doses)",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "1004045004",
            "display": "Intravitreal injection of anti-vascular endothelial growth factor",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "period": {
          "start": "2026-06-02",
          "end": "2026-06-02"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0008"
          ],
          "synthetic_reason": "Synthetic retina-clinic treatment for center-involving macular edema.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "PROC-002",
        "display": "Podiatry: reduction of calluses under the second metatarsal heads, nail care, and fitting for protective and low-heeled stage shoes",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "229826007",
            "display": "Reduction of callus",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "period": {
          "start": "2026-06-09",
          "end": "2026-06-09"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic podiatry visit in the high-risk foot program.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "PROC-004",
        "display": "Right-eye intravitreal anti-VEGF injection (dose 2 of 3)",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "1004045004",
            "display": "Intravitreal injection of anti-vascular endothelial growth factor",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "period": {
          "start": "2026-06-30",
          "end": "2026-06-30"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0008"
          ],
          "synthetic_reason": "Synthetic retina-clinic treatment.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "PROC-005",
        "display": "Right-eye intravitreal anti-VEGF injection (dose 3 of 3)",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "1004045004",
            "display": "Intravitreal injection of anti-vascular endothelial growth factor",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "period": {
          "start": "2026-07-28",
          "end": "2026-07-28"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0008"
          ],
          "synthetic_reason": "Synthetic retina-clinic treatment.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "PROC-006",
        "display": "Right-eye intravitreal anti-VEGF injection (first extended interval, six weeks)",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "1004045004",
            "display": "Intravitreal injection of anti-vascular endothelial growth factor",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "period": {
          "start": "2026-09-08",
          "end": "2026-09-08"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0008"
          ],
          "synthetic_reason": "Synthetic retina-clinic treatment.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "PROC-007",
        "display": "Podiatry: reduction of calluses and nail care, three-month review",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "229826007",
            "display": "Reduction of callus",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "period": {
          "start": "2026-09-14",
          "end": "2026-09-14"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic podiatry visit in the high-risk foot program.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "PROC-008",
        "display": "Right-eye intravitreal anti-VEGF injection (interval extended to eight weeks after this dose)",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "1004045004",
            "display": "Intravitreal injection of anti-vascular endothelial growth factor",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "period": {
          "start": "2026-10-20",
          "end": "2026-10-20"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0008"
          ],
          "synthetic_reason": "Synthetic retina-clinic treatment.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      }
    ],
    "immunizations": [
      {
        "id": "IMM-001",
        "display": "Pneumococcal conjugate vaccine (PCV20)",
        "status": "completed",
        "date": "2026-06-15",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "216",
            "display": "Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic single dose of PCV20 at 70 with no earlier pneumococcal vaccine on record.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "IMM-002",
        "display": "Influenza vaccine, high-dose, 2026-2027 season",
        "status": "completed",
        "date": "2026-10-26",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "135",
            "display": "Influenza, high-dose, trivalent, PF",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic yearly high-dose influenza vaccination at 70.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "IMM-003",
        "display": "Recombinant zoster vaccine, dose 1 of 2",
        "status": "completed",
        "date": "2026-10-26",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "187",
            "display": "zoster recombinant",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic first dose of the recombinant zoster vaccine.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      }
    ],
    "family_history": [
      {
        "id": "FH-001",
        "relationship": {
          "system": "http://terminology.hl7.org/CodeSystem/v3-RoleCode",
          "code": "MTH",
          "display": "mother"
        },
        "condition": "Died suddenly of a heart attack in 1932; age at death not recorded in the cited source",
        "provenance": {
          "evidence_grade": "D",
          "claim_ids": [
            "CLM-0002"
          ],
          "synthetic_reason": null,
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      }
    ],
    "past_medical_history": [
      {
        "id": "PMH-001",
        "display": "Diabetes affecting her eyes, with health problems beginning in the 1970s",
        "historical_date": {
          "iso": "1970",
          "display": "1970s",
          "precision": "decade",
          "calendar": "gregorian"
        },
        "provenance": {
          "evidence_grade": "D",
          "claim_ids": [
            "CLM-0007"
          ],
          "synthetic_reason": null,
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "PMH-002",
        "display": "Cataract surgery, after which she returned to touring more than 40 weeks a year",
        "historical_date": {
          "iso": "1970",
          "display": "1970s",
          "precision": "decade",
          "calendar": "gregorian"
        },
        "provenance": {
          "evidence_grade": "D",
          "claim_ids": [
            "CLM-0008"
          ],
          "synthetic_reason": null,
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "PMH-003",
        "display": "Intensive care admission for heart trouble and quintuple-bypass heart surgery",
        "historical_date": {
          "iso": "1986",
          "display": "1986",
          "precision": "year",
          "calendar": "gregorian"
        },
        "provenance": {
          "evidence_grade": "D",
          "claim_ids": [
            "CLM-0009"
          ],
          "synthetic_reason": null,
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      }
    ],
    "encounters": [
      {
        "id": "ENC-001",
        "display": "New patient visit: diabetes with calf pain on walking, low glucose after late shows, eye and foot examinations, and cardiovascular risk",
        "status": "finished",
        "date": "2026-05-11",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "ENC-002",
        "display": "Two-week review: glucose and hypoglycemia safety on the new plan, and vascular surgery consultation",
        "status": "finished",
        "date": "2026-05-26",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        },
        "visit_type": "chronic_care",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "390906007",
          "display": "Follow-up encounter",
          "validation_status": "validated",
          "validated_on": "2026-11-04"
        },
        "documentation": {
          "chief_complaint": "Two-week review of the new glucose plan, seen the same day by vascular surgery",
          "hpi": {
            "narrative": "Ms. Fitzgerald returns two weeks after her first visit and is seen by Dr. Okafor-Lane of vascular surgery on the same day. She stopped glipizide, moved glargine 24 units to the morning, and started empagliflozin 10 mg and atorvastatin 80 mg. Her continuous glucose monitor shows glucose between 70 and 180 mg/dL 58% of the time, time below 70 mg/dL 0.5%, with a lowest reading of 68 mg/dL after a long rehearsal, and no reading below 54 mg/dL; there have been no lows after shows. She has no burning or itching with urination and no muscle aches. Calf cramping still stops her after about one and a half blocks, more on the right; she has no rest pain or sores. Her right eye remains blurred; the retina clinic will see her next week.",
            "elements": [
              {
                "label": "Glucose",
                "value": "Time in range 58%; time below 70 mg/dL 0.5%; lowest 68 mg/dL; none below 54"
              },
              {
                "label": "Medicines",
                "value": "Glipizide stopped; glargine 24 units each morning; empagliflozin and atorvastatin 80 mg started, no side effects"
              },
              {
                "label": "Claudication",
                "value": "Calf pain after about one and a half blocks; no rest pain"
              },
              {
                "label": "Eyes",
                "value": "Retina clinic appointment next week"
              }
            ]
          },
          "ros": [
            {
              "system": "Cardiovascular",
              "status": "positive",
              "finding": "Calf cramping on walking; no chest pain, rest pain, or ankle swelling"
            },
            {
              "system": "Eyes",
              "status": "positive",
              "finding": "Right-eye blur unchanged"
            },
            {
              "system": "Genitourinary",
              "status": "negative",
              "finding": "No burning, itching, or discharge"
            },
            {
              "system": "Musculoskeletal",
              "status": "negative",
              "finding": "No muscle aches on the higher statin dose"
            },
            {
              "system": "Integumentary",
              "status": "negative",
              "finding": "No foot sores or blisters"
            }
          ],
          "exam": [
            {
              "system": "General",
              "finding": "Well; weight 83.8 kg; blood pressure 124/70, pulse 60"
            },
            {
              "system": "Feet",
              "finding": "Skin intact; calluses under the second metatarsal heads; hammer toes of the second and third toes; no ulcer; monofilament felt at all sites; feet warm with slow capillary refill on the right"
            },
            {
              "system": "Vascular",
              "finding": "Femoral pulses present; popliteal and foot pulses absent on the right; foot pulses faint on the left"
            }
          ],
          "assessment_plan": [
            {
              "problem_id": "PRB-001",
              "display": "Type 2 diabetes with peripheral artery disease",
              "assessment": "No lows below 54 mg/dL since glipizide was stopped and glargine was reduced and moved to the morning. Time in range is 58%; the usual goal is above 70%, or above 50% for an older adult at high risk of lows, and it should rise as empagliflozin takes effect. Dr. Okafor-Lane's arterial duplex shows an occluded right superficial femoral artery with flow restored above the knee and two open arteries to the foot, and a 50 to 69% narrowing of the left superficial femoral artery; no disease above the groin. She has lifestyle-limiting claudication without signs of a threatened limb, so supervised exercise and medicines come first",
              "plan": [
                "Start rivaroxaban 2.5 mg twice daily with aspirin 81 mg",
                "Supervised exercise three times a week for twelve weeks, starting next week, with a home walking plan for tour weeks",
                "No procedure now; vascular review of revascularization after twelve weeks of exercise, sooner for rest pain, a wound, or color change",
                "Podiatry appointment within three weeks"
              ]
            },
            {
              "problem_id": "PRB-002",
              "display": "Diabetic macular edema, right eye",
              "assessment": "Retina clinic appointment next week to start anti-VEGF injections",
              "plan": [
                "Keep the retina appointment"
              ]
            }
          ],
          "monitoring": [
            {
              "domain": "laboratory",
              "measure": "Hemoglobin A1c",
              "cadence": "Every three months when not at goal or after a change; every six months at goal",
              "status": "up_to_date",
              "detail": "8.6% two weeks ago; next at three months",
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Continuous glucose monitor review: time in range and time below range",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Time in range 58%; time below 70 mg/dL 0.5%; none below 54 mg/dL",
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Hypoglycemia events, show-day plan, and glucagon",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "No lows after shows; lowest 68 mg/dL after a long rehearsal; glucagon carried; road manager trained",
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Empagliflozin safety: genital infection, volume, and sick-day rules",
              "cadence": "At the start and every visit",
              "status": "completed_today",
              "detail": "No genital symptoms; sick-day rules reviewed for travel days",
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Creatinine, eGFR, and potassium",
              "cadence": "Within three months of starting an SGLT2 inhibitor, then every six to twelve months; potassium on SGLT2 inhibitor and rivaroxaban review",
              "status": "up_to_date",
              "detail": "Creatinine 0.92 mg/dL, eGFR 67, potassium 4.4 mmol/L two weeks ago; next at three months",
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Lipid panel",
              "cadence": "4 to 12 weeks after a statin or other lipid-lowering change, then yearly",
              "status": "due",
              "detail": "Atorvastatin raised to 80 mg two weeks ago; lipid panel due 4 to 12 weeks after the change",
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026",
                "GL-ACC-PAD-2024"
              ]
            },
            {
              "domain": "examination",
              "measure": "Foot inspection, protective sensation, and pulses",
              "cadence": "Every visit with peripheral artery disease and foot deformity (IWGDF risk 2); podiatry every three to six months",
              "status": "completed_today",
              "detail": "No ulcer; protective sensation intact; calluses and hammer toes; podiatry appointment within three weeks",
              "guideline_ids": [
                "GL-IWGDF-2023",
                "GL-ADA-2026"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Ankle-brachial and toe-brachial indices",
              "cadence": "At diagnosis; repeat with arterial duplex six months after the consultation or with any change in symptoms",
              "status": "up_to_date",
              "detail": "Ankle-brachial index 0.62 right and 0.74 left, toe-brachial index 0.46 and 0.55 at intake; arterial duplex by vascular surgery today",
              "guideline_ids": [
                "GL-ACC-PAD-2024"
              ]
            },
            {
              "domain": "examination",
              "measure": "Walking distance and claudication symptoms",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Calf pain after about one and a half blocks; no rest pain",
              "guideline_ids": [
                "GL-ACC-PAD-2024"
              ]
            },
            {
              "domain": "referral",
              "measure": "Vascular surgery consultation",
              "cadence": "Promptly for claudication with an abnormal ankle-brachial index",
              "status": "completed_today",
              "detail": "Seen by Dr. Okafor-Lane today",
              "guideline_ids": [
                "GL-ACC-PAD-2024"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Supervised exercise therapy",
              "cadence": "Three times a week for twelve weeks",
              "status": "ordered",
              "detail": "Hospital program starts next week; home walking plan for tour weeks",
              "guideline_ids": [
                "GL-ACC-PAD-2024"
              ]
            },
            {
              "domain": "referral",
              "measure": "Retinal examination and visual acuity",
              "cadence": "With each retina-clinic treatment while macular edema is treated; at least yearly in both eyes",
              "status": "ordered",
              "detail": "Retina clinic next week for the right macular edema",
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "examination",
              "measure": "Blood pressure",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "124/70 mmHg, at goal below 130/80",
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "examination",
              "measure": "Weight and BMI",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "83.8 kg",
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Bleeding on rivaroxaban and aspirin",
              "cadence": "At the start and every visit",
              "status": "completed_today",
              "detail": "Starting today; no bleeding history; no anti-inflammatory painkillers",
              "guideline_ids": [
                "GL-ACC-PAD-2024"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Access and equity: tour-date scheduling, video visits, large print, drug costs",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Visits set around tour dates; large-print plan given; rivaroxaban cost checked with her Part D plan",
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            }
          ],
          "follow_up": "Supervised exercise from next week. Retina clinic next week. Podiatry within three weeks. Annual wellness visit in three weeks. Three-month review with A1c, lipids, and kidney tests",
          "guideline_ids": [
            "GL-ADA-2026",
            "GL-IWGDF-2023",
            "GL-ACC-PAD-2024",
            "GL-AHA-CCD-2023",
            "GL-CMID-2026"
          ]
        }
      },
      {
        "id": "ENC-003",
        "display": "Three-month review: A1c, lipids, walking program, eye treatment, and foot care",
        "status": "finished",
        "date": "2026-08-10",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        },
        "visit_type": "chronic_care",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "390906007",
          "display": "Follow-up encounter",
          "validation_status": "validated",
          "validated_on": "2026-11-04"
        },
        "documentation": {
          "chief_complaint": "Three-month review: A1c, lipids, walking program, eye treatment, and foot care",
          "hpi": {
            "narrative": "Ms. Fitzgerald returns three months after her first visit, after a two-week run of concerts. She completed ten weeks of the supervised exercise program and walked to the home plan on tour; she can now walk about three blocks before calf pain, and the pain eases faster. She has had three right-eye injections, and her right eye is clearer. The podiatrist pared her calluses and she now performs in low-heeled custom stage shoes. Her glucose monitor shows time in range 66% and time below 70 mg/dL 0.8%, with no reading below 54 mg/dL; she ate before every late show. She has had no bleeding on rivaroxaban and aspirin. Her hepatitis C screening test was negative. She would like to know whether anything else can help her legs and her glucose.",
            "elements": [
              {
                "label": "Glucose",
                "value": "Time in range 66%; time below 70 mg/dL 0.8%; none below 54"
              },
              {
                "label": "Walking",
                "value": "About three blocks, from one and a half"
              },
              {
                "label": "Eye treatment",
                "value": "Three right-eye injections; vision clearer"
              },
              {
                "label": "Feet",
                "value": "Calluses pared; low-heeled stage shoes"
              },
              {
                "label": "Bleeding",
                "value": "None"
              }
            ]
          },
          "ros": [
            {
              "system": "Cardiovascular",
              "status": "positive",
              "finding": "Calf pain after about three blocks; no chest pain or rest pain"
            },
            {
              "system": "Eyes",
              "status": "positive",
              "finding": "Right-eye blur better"
            },
            {
              "system": "Hematologic",
              "status": "negative",
              "finding": "No bruising, nosebleeds, or blood in the urine or stool"
            },
            {
              "system": "Integumentary",
              "status": "negative",
              "finding": "No foot sores"
            }
          ],
          "exam": [
            {
              "system": "General",
              "finding": "Well; weight 82.1 kg, BMI 30.2; blood pressure 122/68, pulse 62"
            },
            {
              "system": "Feet",
              "finding": "Skin intact; small calluses; hammer toes; no ulcer; monofilament felt at all sites; right foot pulses absent, left faint; shoes fit well"
            },
            {
              "system": "Eyes",
              "finding": "Best-corrected acuity 71 letters right and 81 letters left"
            }
          ],
          "assessment_plan": [
            {
              "problem_id": "PRB-001",
              "display": "Type 2 diabetes with peripheral artery disease",
              "assessment": "A1c 7.6%, from 8.6%, without level 2 lows; still just above her goal below 7.5%. Walking distance has doubled with supervised exercise. With coronary and peripheral artery disease, a GLP-1 receptor agonist adds cardiovascular protection, and in people with peripheral artery disease and type 2 diabetes semaglutide has increased walking distance. Because a fast fall in glucose can briefly worsen retinopathy, the retina clinic was told before the start and the dose will rise slowly. Creatinine 0.96 mg/dL and eGFR 64, a small expected change on empagliflozin; potassium 4.6 mmol/L",
              "plan": [
                "Start semaglutide 0.25 mg weekly for four weeks, then 0.5 mg weekly",
                "Eat smaller meals and stop eating when full; call for persistent vomiting or abdominal pain",
                "Continue glargine 24 units; lower it if fasting readings fall below 90 mg/dL",
                "Finish the twelve weeks of supervised exercise, then walk at least three times a week"
              ]
            },
            {
              "problem_id": "PRB-003",
              "display": "Coronary artery disease after bypass surgery",
              "assessment": "LDL 64 mg/dL on atorvastatin 80 mg, above the goal below 55 mg/dL; HDL 46 and triglycerides 112 mg/dL. No angina",
              "plan": [
                "Add ezetimibe 10 mg daily",
                "Lipid panel in 4 to 12 weeks"
              ]
            },
            {
              "problem_id": "PRB-002",
              "display": "Diabetic macular edema, right eye",
              "assessment": "Acuity 71 letters, from 64, after three injections; the retina clinic will now lengthen the interval",
              "plan": [
                "Continue retina-clinic treatment"
              ]
            }
          ],
          "monitoring": [
            {
              "domain": "laboratory",
              "measure": "Hemoglobin A1c",
              "cadence": "Every three months when not at goal or after a change; every six months at goal",
              "status": "completed_today",
              "detail": "7.6%, from 8.6%",
              "observation_ids": [
                "OBS-A1C-V3"
              ],
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Continuous glucose monitor review: time in range and time below range",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Time in range 66%; time below 70 mg/dL 0.8%; none below 54 mg/dL",
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Hypoglycemia events, show-day plan, and glucagon",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "No level 2 or 3 lows; ate before every late show; glucagon unused",
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Empagliflozin safety: genital infection, volume, and sick-day rules",
              "cadence": "At the start and every visit",
              "status": "completed_today",
              "detail": "No genital infection; no dizziness on stage",
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Creatinine, eGFR, and potassium",
              "cadence": "Within three months of starting an SGLT2 inhibitor, then every six to twelve months; potassium on SGLT2 inhibitor and rivaroxaban review",
              "status": "completed_today",
              "detail": "Creatinine 0.96 mg/dL, eGFR 64, potassium 4.6, sodium 140 mmol/L",
              "observation_ids": [
                "OBS-CR-V3",
                "OBS-EGFR-V3",
                "OBS-K-V3",
                "OBS-NA-V3"
              ],
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Urine albumin-creatinine ratio",
              "cadence": "Yearly",
              "status": "up_to_date",
              "detail": "18 mg/g at intake",
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Lipid panel",
              "cadence": "4 to 12 weeks after a statin or other lipid-lowering change, then yearly",
              "status": "deferred",
              "detail": "Due 4 to 12 weeks after atorvastatin was raised; drawn today at 13 weeks, one week late, because she was on tour. LDL 64 mg/dL, above goal; no harm from the one-week delay. Corrective action: lipid tests after any change are booked before she leaves on tour",
              "observation_ids": [
                "OBS-CHOL-V3",
                "OBS-LDL-V3",
                "OBS-HDL-V3",
                "OBS-TG-V3"
              ],
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026",
                "GL-ACC-PAD-2024"
              ]
            },
            {
              "domain": "examination",
              "measure": "Foot inspection, protective sensation, and pulses",
              "cadence": "Every visit with peripheral artery disease and foot deformity (IWGDF risk 2); podiatry every three to six months",
              "status": "completed_today",
              "detail": "No ulcer; protective sensation intact; podiatry seen in June, next visit in September",
              "guideline_ids": [
                "GL-IWGDF-2023",
                "GL-ADA-2026"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Ankle-brachial and toe-brachial indices",
              "cadence": "At diagnosis; repeat with arterial duplex six months after the consultation or with any change in symptoms",
              "status": "up_to_date",
              "detail": "Repeat with duplex at the six-month vascular review",
              "guideline_ids": [
                "GL-ACC-PAD-2024"
              ]
            },
            {
              "domain": "examination",
              "measure": "Walking distance and claudication symptoms",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "About three blocks before calf pain, from one and a half",
              "guideline_ids": [
                "GL-ACC-PAD-2024"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Supervised exercise therapy",
              "cadence": "Three times a week for twelve weeks",
              "status": "completed_today",
              "detail": "Ten of twelve weeks done; home plan followed on tour",
              "guideline_ids": [
                "GL-ACC-PAD-2024"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Retinal examination and visual acuity",
              "cadence": "With each retina-clinic treatment while macular edema is treated; at least yearly in both eyes",
              "status": "completed_today",
              "detail": "Acuity 71 letters right and 81 left; three injections; retina clinic told about semaglutide",
              "observation_ids": [
                "OBS-VAR-V3",
                "OBS-VAL-V3"
              ],
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "examination",
              "measure": "Blood pressure",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "122/68 mmHg",
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "examination",
              "measure": "Weight and BMI",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "82.1 kg, down 1.9 kg",
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Bleeding on rivaroxaban and aspirin",
              "cadence": "At the start and every visit",
              "status": "completed_today",
              "detail": "No bleeding",
              "guideline_ids": [
                "GL-ACC-PAD-2024"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Semaglutide tolerance: nausea, appetite, and dose step",
              "cadence": "At the start and each dose step",
              "status": "completed_today",
              "detail": "Starting today; nausea and dose steps explained",
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Access and equity: tour-date scheduling, video visits, large print, drug costs",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Semaglutide cost checked with her Part D plan; next visit set before the autumn tour",
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            }
          ],
          "follow_up": "Semaglutide dose step in four weeks, by video visit if she is touring. Podiatry in September. Review in eleven weeks with A1c, lipids, and kidney tests; zoster vaccine dose 1 at that visit",
          "guideline_ids": [
            "GL-ADA-2026",
            "GL-IWGDF-2023",
            "GL-ACC-PAD-2024",
            "GL-AHA-CCD-2023",
            "GL-STRIDE-2025",
            "GL-CMID-2026"
          ]
        }
      },
      {
        "id": "ENC-004",
        "display": "Five-and-a-half-month review: A1c, lipids, walking distance, revascularization decision, foot and eye follow-up",
        "status": "finished",
        "date": "2026-10-26",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        },
        "visit_type": "chronic_care",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "390906007",
          "display": "Follow-up encounter",
          "validation_status": "validated",
          "validated_on": "2026-11-04"
        },
        "documentation": {
          "chief_complaint": "Five-and-a-half-month review: A1c, lipids, walking distance, the revascularization decision, foot and eye follow-up",
          "hpi": {
            "narrative": "Ms. Fitzgerald returns eleven weeks after her three-month visit. She stepped up to semaglutide 0.5 mg weekly in September; she had mild nausea for the first two weeks, which passed, and she has lost 1.5 kg. Her glucose monitor shows time in range 74% and time below 70 mg/dL 0.6%, with no reading below 54 mg/dL. She finished the supervised exercise program and walks most days; she can now walk about five blocks before calf pain, and only climbing slows her. She has no rest pain and no sores. She has had five right-eye injections and the interval is now eight weeks. The podiatrist saw her in September. She has had no bleeding. Her mammogram in July was normal, and the bone density scan is booked between tours. She feels ready for her winter tour.",
            "elements": [
              {
                "label": "Glucose",
                "value": "Time in range 74%; time below 70 mg/dL 0.6%; none below 54"
              },
              {
                "label": "Semaglutide",
                "value": "0.5 mg weekly since September; nausea passed"
              },
              {
                "label": "Walking",
                "value": "About five blocks; no rest pain"
              },
              {
                "label": "Eye treatment",
                "value": "Five injections; now every eight weeks"
              }
            ]
          },
          "ros": [
            {
              "system": "Cardiovascular",
              "status": "positive",
              "finding": "Calf pain only after about five blocks or on hills; no chest pain"
            },
            {
              "system": "Gastrointestinal",
              "status": "negative",
              "finding": "Nausea resolved; no vomiting or abdominal pain"
            },
            {
              "system": "Eyes",
              "status": "negative",
              "finding": "Right-eye vision clearer"
            },
            {
              "system": "Integumentary",
              "status": "negative",
              "finding": "No foot sores"
            }
          ],
          "exam": [
            {
              "system": "General",
              "finding": "Well; weight 80.6 kg, BMI 29.6; blood pressure 120/68, pulse 60"
            },
            {
              "system": "Feet",
              "finding": "Skin intact; minimal callus; hammer toes; no ulcer; monofilament felt at all sites; right foot pulses absent, left faint; feet warm"
            },
            {
              "system": "Eyes",
              "finding": "Best-corrected acuity 75 letters right and 81 letters left"
            }
          ],
          "assessment_plan": [
            {
              "problem_id": "PRB-001",
              "display": "Type 2 diabetes with peripheral artery disease",
              "assessment": "A1c 7.1%, at her goal below 7.5%, with no level 2 or 3 lows. After supervised exercise she walks about five blocks, and claudication no longer limits her daily life or her performing, so revascularization is not needed now; Dr. Okafor-Lane agrees by message. Creatinine 0.94 mg/dL, eGFR 65, potassium 4.5 mmol/L",
              "plan": [
                "Continue metformin, empagliflozin, semaglutide 0.5 mg weekly, and glargine 24 units",
                "Walk at least three times a week for life",
                "Vascular review with ankle-brachial index and duplex next month, as planned",
                "Podiatry every three months; foot check at every visit"
              ]
            },
            {
              "problem_id": "PRB-003",
              "display": "Coronary artery disease after bypass surgery",
              "assessment": "LDL 48 mg/dL, at goal, on atorvastatin 80 mg and ezetimibe; total cholesterol 114, HDL 47, triglycerides 96 mg/dL",
              "plan": [
                "Continue atorvastatin, ezetimibe, aspirin, rivaroxaban, and metoprolol",
                "Lipid panel yearly"
              ]
            },
            {
              "display": "Immunizations",
              "assessment": "Influenza and recombinant zoster vaccines due this autumn, as planned at the wellness visit",
              "plan": [
                "High-dose influenza vaccine and recombinant zoster vaccine dose 1 given today; zoster dose 2 in two to six months; COVID-19 and RSV vaccines at her pharmacy before the winter tour"
              ]
            },
            {
              "problem_id": "PRB-002",
              "display": "Diabetic macular edema, right eye",
              "assessment": "Acuity 75 letters, from 64 at intake; no worsening of retinopathy reported by the retina clinic since semaglutide began",
              "plan": [
                "Continue retina-clinic treatment every eight weeks; left eye examined at each visit"
              ]
            }
          ],
          "monitoring": [
            {
              "domain": "laboratory",
              "measure": "Hemoglobin A1c",
              "cadence": "Every three months when not at goal or after a change; every six months at goal",
              "status": "completed_today",
              "detail": "7.1%, at goal; every six months from now",
              "observation_ids": [
                "OBS-A1C-V4"
              ],
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Continuous glucose monitor review: time in range and time below range",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Time in range 74%; time below 70 mg/dL 0.6%",
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Hypoglycemia events, show-day plan, and glucagon",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "No level 2 or 3 lows since intake",
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Empagliflozin safety: genital infection, volume, and sick-day rules",
              "cadence": "At the start and every visit",
              "status": "completed_today",
              "detail": "No side effects",
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Creatinine, eGFR, and potassium",
              "cadence": "Within three months of starting an SGLT2 inhibitor, then every six to twelve months; potassium on SGLT2 inhibitor and rivaroxaban review",
              "status": "completed_today",
              "detail": "Creatinine 0.94 mg/dL, eGFR 65, potassium 4.5, sodium 139 mmol/L",
              "observation_ids": [
                "OBS-CR-V4",
                "OBS-EGFR-V4",
                "OBS-K-V4",
                "OBS-NA-V4"
              ],
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Urine albumin-creatinine ratio",
              "cadence": "Yearly",
              "status": "up_to_date",
              "detail": "18 mg/g at intake; repeat at the next yearly check",
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Lipid panel",
              "cadence": "4 to 12 weeks after a statin or other lipid-lowering change, then yearly",
              "status": "completed_today",
              "detail": "LDL 48 mg/dL eleven weeks after ezetimibe was added, at goal",
              "observation_ids": [
                "OBS-CHOL-V4",
                "OBS-LDL-V4",
                "OBS-HDL-V4",
                "OBS-TG-V4"
              ],
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026",
                "GL-ACC-PAD-2024"
              ]
            },
            {
              "domain": "examination",
              "measure": "Foot inspection, protective sensation, and pulses",
              "cadence": "Every visit with peripheral artery disease and foot deformity (IWGDF risk 2); podiatry every three to six months",
              "status": "completed_today",
              "detail": "No ulcer; podiatry in September; next in December",
              "guideline_ids": [
                "GL-IWGDF-2023",
                "GL-ADA-2026"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Ankle-brachial and toe-brachial indices",
              "cadence": "At diagnosis; repeat with arterial duplex six months after the consultation or with any change in symptoms",
              "status": "due",
              "detail": "With arterial duplex at the vascular review next month, six months after the consultation",
              "guideline_ids": [
                "GL-ACC-PAD-2024"
              ]
            },
            {
              "domain": "examination",
              "measure": "Walking distance and claudication symptoms",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "About five blocks; claudication no longer limits her",
              "guideline_ids": [
                "GL-ACC-PAD-2024"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Supervised exercise therapy",
              "cadence": "Three times a week for twelve weeks",
              "status": "completed_today",
              "detail": "Program completed; walking most days",
              "guideline_ids": [
                "GL-ACC-PAD-2024"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Retinal examination and visual acuity",
              "cadence": "With each retina-clinic treatment while macular edema is treated; at least yearly in both eyes",
              "status": "completed_today",
              "detail": "Acuity 75 letters right and 81 left; five injections",
              "observation_ids": [
                "OBS-VAR-V4",
                "OBS-VAL-V4"
              ],
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "examination",
              "measure": "Blood pressure",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "120/68 mmHg",
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "examination",
              "measure": "Weight and BMI",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "80.6 kg, down 3.4 kg since intake",
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Bleeding on rivaroxaban and aspirin",
              "cadence": "At the start and every visit",
              "status": "completed_today",
              "detail": "No bleeding",
              "guideline_ids": [
                "GL-ACC-PAD-2024"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Semaglutide tolerance: nausea, appetite, and dose step",
              "cadence": "At the start and each dose step",
              "status": "completed_today",
              "detail": "0.5 mg weekly; nausea passed",
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Access and equity: tour-date scheduling, video visits, large print, drug costs",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Video visit planned during the winter tour; prescriptions synchronized for travel",
              "guideline_ids": [
                "GL-ADA-2026",
                "GL-CMID-2026"
              ]
            }
          ],
          "follow_up": "Vascular review with ankle-brachial index and duplex next month. Podiatry in December. Retina clinic every eight weeks. Video visit during the winter tour; in-person review in three months with A1c",
          "guideline_ids": [
            "GL-ADA-2026",
            "GL-IWGDF-2023",
            "GL-ACC-PAD-2024",
            "GL-AHA-CCD-2023",
            "GL-STRIDE-2025",
            "GL-CMID-2026"
          ]
        }
      },
      {
        "id": "ENC-005",
        "display": "Subsequent annual wellness visit",
        "status": "finished",
        "date": "2026-06-15",
        "visit_type": "annual_wellness_subsequent",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "281038008",
          "display": "Geriatric annual health check",
          "validation_status": "validated",
          "validated_on": "2026-11-04"
        },
        "documentation": {
          "chief_complaint": "Subsequent annual wellness visit",
          "billing_note": "HCPCS G0439 (subsequent annual wellness visit) with CPT 99497 (advance care planning) and G0009 with CPT 90677 (pneumococcal vaccine and its administration), all on the same day",
          "health_risk_assessment_method": "Completed with a medical assistant reading the questions aloud, because of her right-eye vision, and reviewed with her by Dr. Whitlow",
          "hpi": {
            "narrative": "Ms. Fitzgerald is a 70-year-old singer with type 2 diabetes and peripheral artery disease, macular edema in the right eye, and coronary bypass surgery last year, who comes for her subsequent annual wellness visit five weeks after her first visit and three weeks after her vascular surgery consultation. Since glipizide was stopped and glargine was moved to the morning, her continuous glucose monitor has shown one reading of 66 mg/dL, on a travel day when lunch was late, and none below 54. She started low-dose rivaroxaban with her aspirin after the consultation and has had no bleeding. She has had two weeks of the supervised walking program and can already walk a little farther. She had her first injection in the right eye two weeks ago and saw the podiatrist last week, who pared the calluses and measured her for low-heeled stage shoes. She has a two-week run of concerts starting next month.",
            "elements": [
              {
                "label": "Visit",
                "value": "Subsequent annual wellness visit"
              },
              {
                "label": "Glucose",
                "value": "One reading of 66 mg/dL on a travel day; none below 54 mg/dL"
              },
              {
                "label": "New since intake",
                "value": "Empagliflozin, glargine in the morning, rivaroxaban 2.5 mg twice daily, continuous glucose monitor"
              },
              {
                "label": "Walking program",
                "value": "Supervised exercise three times a week for two weeks"
              },
              {
                "label": "Eye and foot care",
                "value": "First right-eye injection two weeks ago; podiatry last week"
              },
              {
                "label": "Functional status",
                "value": "Independent; walks about two blocks; uses a wheelchair in large airports"
              }
            ]
          },
          "health_risk_assessment": [
            {
              "domain": "Self-rated health",
              "finding": "Good, and better than last year after the heart surgery"
            },
            {
              "domain": "Psychosocial",
              "finding": "Her music and audiences give her purpose; her band and road manager are close; no loneliness"
            },
            {
              "domain": "Behavioral",
              "finding": "No tobacco; alcohol rarely; meals irregular on tour; walking program three times a week; sleeps about seven hours, later on show nights"
            },
            {
              "domain": "Activities of daily living",
              "finding": "Independent in bathing, dressing, eating, toileting, and transfers"
            },
            {
              "domain": "Instrumental activities of daily living",
              "finding": "Manages her medicines with a weekly organizer; her road manager handles travel; does not drive"
            },
            {
              "domain": "Home safety",
              "finding": "Smoke detectors working; rugs secured; good lighting; no firearm"
            },
            {
              "domain": "Falls",
              "finding": "No falls in the past year; careful on stage steps"
            },
            {
              "domain": "Hearing and vision",
              "finding": "No hearing concern; right-eye vision blurred, under treatment; lens implants in both eyes"
            },
            {
              "domain": "Bladder",
              "finding": "No incontinence; urinates a little more since empagliflozin"
            },
            {
              "domain": "Memory",
              "finding": "No concerns; learns new songs easily"
            }
          ],
          "ros": [
            {
              "system": "Constitutional",
              "status": "negative",
              "finding": "Weight down 0.6 kg; no fever or fatigue"
            },
            {
              "system": "Eyes",
              "status": "positive",
              "finding": "Right-eye blur, slightly better since the injection; no eye pain or redness"
            },
            {
              "system": "Ears, nose, mouth, and throat",
              "status": "negative",
              "finding": "No hearing change; voice strong"
            },
            {
              "system": "Cardiovascular",
              "status": "positive",
              "finding": "Calf cramping after about two blocks; no chest pain, breathlessness, palpitations, or ankle swelling"
            },
            {
              "system": "Respiratory",
              "status": "negative",
              "finding": "No cough or breathlessness"
            },
            {
              "system": "Gastrointestinal",
              "status": "negative",
              "finding": "No nausea, diarrhea, or blood in the stool"
            },
            {
              "system": "Genitourinary",
              "status": "negative",
              "finding": "No burning, itching, or discharge on empagliflozin"
            },
            {
              "system": "Musculoskeletal",
              "status": "negative",
              "finding": "No joint pain limiting walking"
            },
            {
              "system": "Integumentary",
              "status": "negative",
              "finding": "No foot sores or blisters on daily checks"
            },
            {
              "system": "Neurological",
              "status": "negative",
              "finding": "No numbness, tingling, or weakness"
            },
            {
              "system": "Psychiatric",
              "status": "negative",
              "finding": "Mood good; PHQ-2 score 0"
            },
            {
              "system": "Endocrine",
              "status": "negative",
              "finding": "No shakiness or sweating since the plan changed, apart from one mild low on a travel day"
            },
            {
              "system": "Hematologic",
              "status": "negative",
              "finding": "No bruising, nosebleeds, or bleeding gums on rivaroxaban and aspirin"
            }
          ],
          "exam": [
            {
              "system": "Constitutional",
              "finding": "Well and animated; weight 83.4 kg, BMI 30.6; blood pressure 124/68"
            },
            {
              "system": "Eyes",
              "finding": "Lens implants in both eyes; injection site in the right eye healed; no redness"
            },
            {
              "system": "Ears, nose, and throat",
              "finding": "Whispered voice heard in both ears"
            },
            {
              "system": "Cardiovascular",
              "finding": "Regular rhythm; healed sternotomy scar; no murmur; femoral pulses present; right foot pulses absent and left faint, as before"
            },
            {
              "system": "Respiratory",
              "finding": "Clear to auscultation bilaterally"
            },
            {
              "system": "Feet",
              "finding": "Calluses pared; hammer toes; skin intact; no ulcer; protective sensation intact"
            },
            {
              "system": "Musculoskeletal",
              "finding": "Timed Up and Go 11 seconds without an aid"
            },
            {
              "system": "Neurological",
              "finding": "Oriented; recall and reasoning normal; Mini-Cog 5 of 5"
            },
            {
              "system": "Psychiatric",
              "finding": "Euthymic and engaged"
            },
            {
              "system": "Skin",
              "finding": "No suspicious lesions on the exposed skin"
            }
          ],
          "assessment_plan": [
            {
              "display": "Subsequent annual wellness visit completed",
              "assessment": "Health risk assessment reviewed, personalized prevention plan updated, and a large-print copy given. Depression, alcohol, and cognitive screens are normal. Fall risk is low by the Timed Up and Go, with calf pain and right-eye vision as the main risks",
              "plan": [
                "PCV20 given today",
                "Mammogram and bone density scan ordered",
                "Next annual wellness visit in one year"
              ]
            },
            {
              "problem_id": "PRB-001",
              "display": "Type 2 diabetes with peripheral artery disease",
              "assessment": "No level 2 low since glipizide was stopped. The first weeks of supervised exercise are going well. Bleeding precautions on rivaroxaban and aspirin reviewed",
              "plan": [
                "Continue the current plan",
                "Continue supervised exercise three times a week; on tour, the home walking plan the exercise program wrote for her",
                "Three-month review in eight weeks with A1c, lipids, and kidney tests"
              ]
            }
          ],
          "prevention_plan": [
            {
              "service": "Influenza vaccine",
              "status": "due",
              "detail": "High-dose or adjuvanted vaccine due in the autumn",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "service": "COVID-19 vaccine",
              "status": "due",
              "detail": "Recommended at 65 and older; due in the autumn",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "service": "Pneumococcal vaccine",
              "status": "completed_today",
              "detail": "PCV20 given today; no further doses needed",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "service": "Recombinant zoster vaccine",
              "status": "due",
              "detail": "Dose 1 at the autumn review with the influenza vaccine, dose 2 two to six months later",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "service": "RSV vaccine",
              "status": "due",
              "detail": "Recommended at 60 to 74 with diabetes complications and heart disease; one dose before the respiratory season",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "service": "Tetanus, diphtheria, and pertussis",
              "status": "up_to_date",
              "detail": "Tdap four years ago",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "service": "Breast cancer screening",
              "status": "ordered",
              "detail": "Mammogram every two years to 74; last one two years ago",
              "guideline_ids": [
                "GL-USPSTF-BREAST-2024"
              ]
            },
            {
              "service": "Colorectal cancer screening",
              "status": "up_to_date",
              "detail": "Normal colonoscopy four years ago; next due at ten years, with the decision individualized after 75",
              "guideline_ids": [
                "GL-USPSTF-CRC-2021"
              ]
            },
            {
              "service": "Osteoporosis screening",
              "status": "ordered",
              "detail": "Bone density scan recommended at 65 and older; none on record",
              "guideline_ids": [
                "GL-USPSTF-OSTEO-2025"
              ]
            },
            {
              "service": "Hepatitis C screening",
              "status": "ordered",
              "detail": "One-time screening for adults through 79; added to the three-month tests",
              "guideline_ids": [
                "GL-USPSTF-HCV-2020"
              ]
            },
            {
              "service": "Depression screening",
              "status": "completed_today",
              "detail": "PHQ-2 score 0",
              "guideline_ids": [
                "GL-USPSTF-DEP-2023"
              ]
            },
            {
              "service": "Alcohol misuse screening",
              "status": "completed_today",
              "detail": "AUDIT-C score 1",
              "guideline_ids": [
                "GL-USPSTF-ALC-2018"
              ]
            },
            {
              "service": "Cognitive assessment",
              "status": "completed_today",
              "detail": "Mini-Cog 5 of 5",
              "guideline_ids": [
                "GL-AWV-CMS"
              ]
            },
            {
              "service": "Falls prevention",
              "status": "completed_today",
              "detail": "Timed Up and Go 11 seconds; no falls; exercise program under way",
              "guideline_ids": [
                "GL-USPSTF-FALLS-2024"
              ]
            },
            {
              "service": "Diabetic eye examination",
              "status": "up_to_date",
              "detail": "Retina clinic treating the right macular edema; both eyes examined",
              "guideline_ids": [
                "GL-ADA-2026"
              ]
            },
            {
              "service": "Diabetic foot examination",
              "status": "completed_today",
              "detail": "No ulcer; podiatry every three months",
              "guideline_ids": [
                "GL-IWGDF-2023"
              ]
            },
            {
              "service": "Kidney screening",
              "status": "up_to_date",
              "detail": "eGFR 67 and urine albumin-creatinine ratio 18 mg/g at intake",
              "guideline_ids": [
                "GL-ADA-2026"
              ]
            },
            {
              "service": "Lung cancer and abdominal aortic aneurysm screening",
              "status": "not_indicated",
              "detail": "She has never smoked",
              "guideline_ids": [
                "GL-PREV-2026"
              ]
            }
          ],
          "advance_care_planning": "Voluntary advance care planning discussion of about 18 minutes, with her consent. She reviewed the written directive she made before her heart surgery and confirmed a health care agent, recorded in the confidential part of the chart and not named here. She said that what matters most to her is to keep singing and travelling for as long as she can, and to keep her sight. She will review the directive yearly.",
          "follow_up": "Mammogram and bone density scan to be scheduled between tour dates. Three-month review in eight weeks with A1c, lipids, kidney tests, and hepatitis C screening. Next annual wellness visit in one year",
          "guideline_ids": [
            "GL-AWV-CMS",
            "GL-PREV-2026",
            "GL-ADA-2026",
            "GL-CDC-IMZ-2026",
            "GL-CMID-2026"
          ]
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic Medicare annual wellness visit; no synthetic illness episode is added under the recent-death rule.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      }
    ],
    "vital_sign_sets": [
      {
        "id": "VSET-001",
        "date": "2026-05-11",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 165,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 84.0,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 30.9,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 126,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 70,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 62,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 16,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.6,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 97,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seated vital signs; no measurement from her lifetime is used.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "VSET-002",
        "date": "2026-05-26",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 165,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 83.8,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 30.8,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 124,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 70,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 60,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 16,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.5,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 97,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seated vital signs; no measurement from her lifetime is used.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "VSET-003",
        "date": "2026-08-10",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 165,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 82.1,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 30.2,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 122,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 68,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 62,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 16,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.6,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 97,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seated vital signs; no measurement from her lifetime is used.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "VSET-004",
        "date": "2026-10-26",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 165,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 80.6,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 29.6,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 120,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 68,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 60,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 16,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.6,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 98,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seated vital signs; no measurement from her lifetime is used.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "VSET-005",
        "date": "2026-06-15",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 165,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 83.4,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 30.6,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 124,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 68,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 60,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 16,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.6,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 97,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seated vital signs at the annual wellness visit.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      }
    ],
    "social_history": [
      {
        "id": "SOC-001",
        "display": "Singer; back on stage since recovering from her heart surgery, touring in the United States and overseas, often two or three late shows a week with long travel days and meals at irregular times; performing is the center of her life",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0003",
            "CLM-0008",
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic modern work history anchored to her documented career and touring.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "SOC-002",
        "display": "Lives in her own home; a road manager and her musicians travel with her; a long-time dresser helps her prepare for shows. She decides who is told about her health",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic living situation; the road manager and dresser are unnamed synthetic people, and no real person is given a role.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "SOC-003",
        "display": "Tobacco: does not smoke. Alcohol: rarely (AUDIT-C at the wellness visit). No other drugs",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic substance history.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "SOC-004",
        "display": "Activity: stands for long sets on stage in heeled shoes; walks little off stage because of calf pain",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic activity history.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "SOC-005",
        "display": "Access and equity: Medicare with a Part D plan and a supplemental plan; misses appointments when touring; reads standard print with difficulty because of her right eye. The clinic schedules around tour dates, uses video visits on the road, sends large-print instructions, checks drug costs before prescribing, and coordinates with clinics in tour cities",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic access plan for the modern episode.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "SOC-006",
        "display": "Supports and strengths: her music, her audiences, her band and road manager, and decades of experience of her own body on the road",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0003",
            "CLM-0004"
          ],
          "synthetic_reason": "Synthetic strengths and supports.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      }
    ],
    "functional_status": [
      {
        "id": "FUNC-001",
        "display": "Independent in all activities of daily living; walks about one and a half blocks before calf pain stops her; uses a wheelchair in large airports; stands through 75-minute sets",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic functional status; not a claim about her real function at this age.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      }
    ],
    "mental_status": [
      {
        "id": "MSE-001",
        "display": "Alert, warm, and engaged; worried about her legs and her eyes and determined to keep performing",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic mental-status finding.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      }
    ],
    "consultation": {
      "referral": {
        "question": "Claudication of both calves, worse on the right, in a 70-year-old touring singer with type 2 diabetes, coronary bypass surgery last year, and an ankle-brachial index of 0.62 right and 0.74 left. Please define the arterial disease, advise on exercise and antithrombotic therapy, and tell us whether and when revascularization should be considered, so that her limbs are protected before any tissue is lost",
        "urgency": "Within two to three weeks, on the same day as her two-week primary care visit",
        "pertinent_history": "Calf cramping after about one and a half blocks for about a year, now limiting her walks through airports and to the stage; no rest pain, wounds, or color change. Diabetes for many years with retinopathy; A1c 8.6% with low glucose readings after late shows, so glipizide was stopped today, glargine reduced to 24 units and moved to the morning, and empagliflozin started. Five-vessel coronary bypass surgery last year; no angina; on aspirin 81 mg, metoprolol succinate 25 mg, and atorvastatin, raised today from 40 to 80 mg for an LDL of 92 mg/dL. Never smoked. Examination: femoral pulses present; popliteal and foot pulses absent on the right and foot pulses faint on the left; calluses under the second metatarsal heads and hammer toes; protective sensation intact; no ulcer (IWGDF risk category 2). Ankle-brachial index 0.62 right and 0.74 left; toe-brachial index 0.46 and 0.55. Creatinine 0.92 mg/dL, eGFR 67, potassium 4.4 mmol/L; urine albumin-creatinine ratio 18 mg/g; hemoglobin 12.4 g/dL. Right macular edema; retina clinic appointment pending. She tours in the United States and overseas and wants to keep performing; she decides who is told about her health",
        "questions": [
          "Where is the arterial disease, and how severe is it?",
          "Is supervised exercise therapy appropriate, and how should it fit around her touring?",
          "Should antithrombotic therapy change, for example low-dose rivaroxaban with aspirin?",
          "Is revascularization indicated now, and what would make it indicated later?",
          "How often should her arteries and feet be reviewed, and what findings need urgent vascular review?"
        ]
      },
      "consultant_note": {
        "history": "Ms. Fitzgerald, a 70-year-old singer, is seen at the request of Dr. Whitlow for calf pain on walking. For about a year both calves have cramped after one and a half blocks, the right sooner, easing within minutes of rest; she uses a wheelchair in large airports. She has no pain at rest or at night, no wounds, and no color change. She had five-vessel coronary bypass surgery last year and has no angina. She has diabetes with retinopathy and has never smoked. She has had no bleeding problems. She stands through long sets on stage and wants to keep touring",
        "data_reviewed": "Dr. Whitlow's intake note and today's two-week note. Ankle-brachial index 0.62 right and 0.74 left; toe-brachial index 0.46 and 0.55. Creatinine 0.92 mg/dL, eGFR 67; hemoglobin 12.4 g/dL; LDL 92 mg/dL; A1c 8.6%. Arterial duplex in the vascular laboratory today: aortoiliac and common femoral arteries without significant narrowing; right superficial femoral artery occluded for about 9 cm in its middle third, with flow restored in the above-knee popliteal artery and two open tibial arteries to the foot; left superficial femoral artery narrowed by 50 to 69% with an open popliteal artery and three tibial arteries; calcified tibial arteries on both sides",
        "exam": [
          {
            "system": "Vascular",
            "finding": "Femoral pulses present and equal; popliteal and foot pulses absent on the right; foot pulses faint on the left; no bruits over the abdomen"
          },
          {
            "system": "Feet",
            "finding": "Warm; slow capillary refill on the right; no pallor on elevation or dependent rubor; skin intact; calluses and hammer toes; no ulcer or gangrene"
          },
          {
            "system": "Neurological",
            "finding": "Protective sensation intact to the monofilament"
          }
        ],
        "assessment": [
          {
            "problem_id": "PRB-001",
            "display": "Type 2 diabetes with peripheral artery disease",
            "assessment": "Femoropopliteal peripheral artery disease in both legs: a right superficial femoral artery occlusion and a moderate left superficial femoral artery stenosis, with good flow to the feet. She has lifestyle-limiting claudication without signs of chronic limb-threatening ischemia (no rest pain, wound, or gangrene), so the limb is not at immediate risk. The first steps are supervised exercise therapy and medical therapy, which improve walking and lower the risk of heart attack, stroke, and limb events. Revascularization is considered when claudication still limits her life after a trial of exercise and medicines, and urgently if a wound, rest pain, or color change appears. Because amputation is more common in people with diabetes, and more common still, and more often done without a vascular assessment first, in Black Americans and in people with less access to care, she should have a low threshold for prompt vascular review of any foot problem"
          },
          {
            "problem_id": "PRB-003",
            "display": "Coronary artery disease after bypass surgery",
            "assessment": "Disease in two vascular beds. Low-dose rivaroxaban with aspirin lowers the risk of major cardiovascular and limb events in symptomatic peripheral artery disease, and her bleeding risk is low (no earlier bleeding, normal hemoglobin and kidney function, no anti-inflammatory painkillers)"
          }
        ],
        "recommendations": [
          "No revascularization now",
          "Supervised exercise therapy: treadmill walking to moderate calf pain, 30 to 45 minutes three times a week for twelve weeks, with a structured home walking plan for tour weeks",
          "Start rivaroxaban 2.5 mg twice daily with aspirin 81 mg daily; avoid anti-inflammatory painkillers",
          "Continue atorvastatin 80 mg and add ezetimibe if LDL stays at 55 mg/dL or above; a GLP-1 receptor agonist such as semaglutide, which increased walking distance in people with peripheral artery disease and type 2 diabetes, is worth considering when her glucose plan is reviewed",
          "Reassess after twelve weeks of exercise; if claudication still limits her life, consider endovascular treatment of the right superficial femoral artery",
          "Urgent vascular review, the same or next day, for rest pain, a foot wound that does not heal within two weeks, or a cold, pale, or dark toe",
          "Vascular review with ankle-brachial index and duplex in six months, and yearly after that if stable",
          "High-risk foot program with podiatry every three months and protective, low-heeled shoes on and off stage"
        ],
        "communication": "Discussed with Dr. Whitlow, who saw her the same day. The findings and choices were explained to Ms. Fitzgerald, who chose to begin supervised exercise and rivaroxaban; she decides who else receives this note",
        "follow_up": "Message review with Dr. Whitlow after twelve weeks of supervised exercise; vascular clinic in six months with ankle-brachial index and duplex; sooner for any of the urgent signs"
      },
      "guideline_ids": [
        "GL-ACC-PAD-2024",
        "GL-IWGDF-PAD-2023",
        "GL-IWGDF-2023",
        "GL-ADA-2026",
        "GL-STRIDE-2025"
      ]
    }
  },
  "care_plan": {
    "health_concerns": [
      {
        "id": "HC-001",
        "display": "Her calves cramp when she walks through airports and to the stage, and she is afraid of what that means for her legs",
        "status": "active",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic patient-centered concern linked to her documented circulatory complications.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "HC-002",
        "display": "Her glucose has dropped low after late shows, once just before an encore",
        "status": "active",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic patient-centered concern.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "HC-003",
        "display": "The vision in her right eye has blurred, and she worries about reading lyrics and set lists",
        "status": "active",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0008"
          ],
          "synthetic_reason": "Synthetic patient-centered concern linked to her documented eye problems.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      }
    ],
    "goals": [
      {
        "id": "GOAL-001",
        "display": "No glucose below 70 mg/dL on most days and no level 2 or 3 low (below 54 mg/dL or needing help) through six months",
        "status": "completed",
        "target_date": "2026-10-26",
        "outcome": "No level 2 or 3 lows since intake; time below 70 mg/dL under 1%",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic hypoglycemia-safety goal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "GOAL-002",
        "display": "A1c below 7.5% by six months",
        "status": "completed",
        "target_date": "2026-10-26",
        "outcome": "A1c 7.1%",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic individualized glycemic goal for a healthy older adult on insulin.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "GOAL-003",
        "display": "LDL cholesterol below 55 mg/dL by six months",
        "status": "completed",
        "target_date": "2026-10-26",
        "outcome": "LDL 48 mg/dL on atorvastatin 80 mg and ezetimibe",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic lipid goal with coronary and peripheral artery disease.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "GOAL-004",
        "display": "Walk at least four blocks without stopping by six months",
        "status": "completed",
        "target_date": "2026-10-26",
        "outcome": "Walks about five blocks before calf pain",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic walking goal set with her.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "GOAL-005",
        "display": "No foot ulcer, and protective footwear on and off stage, through six months",
        "status": "completed",
        "target_date": "2026-10-26",
        "outcome": "No ulcer; low-heeled custom stage shoes and protective daily shoes",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic foot-protection goal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      }
    ],
    "interventions": [
      {
        "id": "INT-001",
        "display": "Comprehensive diabetic foot program: foot inspection, monofilament and vibration testing, and pulses at every visit; IWGDF risk category 2 with podiatry every three months for callus and nail care; protective daily shoes and low-heeled custom stage shoes; daily self-inspection with a magnifying mirror or her dresser's help; and same-day care for any blister, wound, or color change",
        "status": "completed",
        "guideline_ids": [
          "GL-IWGDF-2023",
          "GL-ADA-2026",
          "GL-CMID-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic foot-protection plan.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "INT-002",
        "display": "Vascular surgery consultation for claudication with an ankle-brachial index of 0.62: arterial duplex, supervised exercise therapy, and whether and when revascularization should be considered, before any loss of tissue",
        "status": "completed",
        "guideline_ids": [
          "GL-ACC-PAD-2024",
          "GL-IWGDF-PAD-2023"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic specialist consultation.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "INT-003",
        "display": "Hypoglycemia safety on tour: glipizide stopped; glargine reduced 20% and moved to the morning, at a fixed clock time with written time-zone steps; a continuous glucose monitor with low alerts shared, with her consent, with her road manager; a glucose check before each show and a meal before late shows; glucose tablets in the dressing room and at the side of the stage; nasal glucagon with the road manager trained; and the beta-blocker's effect on warning signs explained",
        "status": "completed",
        "guideline_ids": [
          "GL-ADA-2026",
          "GL-CMID-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic hypoglycemia-safety plan.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "INT-004",
        "display": "Glucose-lowering medicines with heart and kidney benefit: empagliflozin 10 mg started, with sick-day rules (hold on days she cannot eat or drink and before surgery), genital hygiene advice, and a foot check at each visit; metformin continued with vitamin B12 checked; A1c every three months until at goal (goal below 7.5%)",
        "status": "completed",
        "guideline_ids": [
          "GL-ADA-2026",
          "GL-CMID-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010",
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic glucose-lowering plan.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "INT-005",
        "display": "Cardiovascular protection: atorvastatin raised to 80 mg with a lipid panel 4 to 12 weeks later and a goal LDL below 55 mg/dL; aspirin and metoprolol continued; blood pressure goal below 130/80 mmHg",
        "status": "completed",
        "guideline_ids": [
          "GL-ADA-2026",
          "GL-ACC-PAD-2024",
          "GL-AHA-CCD-2023",
          "GL-CMID-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic cardiovascular plan.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "INT-006",
        "display": "Eye care: retina clinic appointment within two weeks for the right macular edema, for anti-VEGF injections; retinal examination of both eyes at least yearly and more often while being treated; large-print materials",
        "status": "completed",
        "guideline_ids": [
          "GL-ADA-2026",
          "GL-CMID-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0008"
          ],
          "synthetic_reason": "Synthetic eye-care plan.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "INT-007",
        "display": "Kidney and laboratory monitoring: creatinine, eGFR and potassium at three months and then every six to twelve months, urine albumin-creatinine ratio yearly, liver tests after the statin change if symptoms, and vitamin B12 periodically on metformin",
        "status": "completed",
        "guideline_ids": [
          "GL-ADA-2026",
          "GL-CMID-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic monitoring plan.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "INT-008",
        "display": "Access and equity: scheduling around tour dates, video visits on the road, large-print instructions, drug-cost checks before prescribing, coordination with clinics in tour cities, and diabetes self-management education and medical nutrition therapy timed to her touring",
        "status": "completed",
        "guideline_ids": [
          "GL-ADA-2026",
          "GL-ACC-PAD-2024"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic access plan.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        }
      },
      {
        "id": "INT-009",
        "display": "Supervised exercise therapy for claudication: treadmill walking to moderate calf pain, 30 to 45 minutes three times a week for twelve weeks at a hospital program, with a structured home walking plan for tour weeks; then walking at least three times a week for life",
        "status": "completed",
        "guideline_ids": [
          "GL-ACC-PAD-2024"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic exercise plan decided at the consultation.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        },
        "recorded_date": "2026-05-26"
      },
      {
        "id": "INT-010",
        "display": "Low-dose rivaroxaban 2.5 mg twice daily with aspirin 81 mg to lower the risk of heart attack, stroke, and major limb events, with bleeding precautions and no anti-inflammatory painkillers",
        "status": "completed",
        "guideline_ids": [
          "GL-ACC-PAD-2024",
          "GL-ADA-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010",
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic antithrombotic plan decided at the consultation.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        },
        "recorded_date": "2026-05-26"
      },
      {
        "id": "INT-011",
        "display": "Revascularization plan: no procedure now; endovascular treatment of the right superficial femoral artery to be considered if claudication still limits her life after twelve weeks of supervised exercise and medical therapy; urgent vascular review for rest pain, a wound, or color change; ankle-brachial index and duplex at six months",
        "status": "completed",
        "guideline_ids": [
          "GL-ACC-PAD-2024",
          "GL-IWGDF-PAD-2023"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010"
          ],
          "synthetic_reason": "Synthetic revascularization plan decided at the consultation.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        },
        "recorded_date": "2026-05-26"
      },
      {
        "id": "INT-012",
        "display": "Semaglutide 0.25 mg weekly for four weeks, then 0.5 mg weekly, for cardiovascular benefit and walking distance, with the retina clinic told before the start because a fast fall in glucose can briefly worsen retinopathy; ezetimibe 10 mg added for an LDL of 64 mg/dL",
        "status": "completed",
        "guideline_ids": [
          "GL-ADA-2026",
          "GL-STRIDE-2025",
          "GL-CMID-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0010",
            "CLM-0009"
          ],
          "synthetic_reason": "Synthetic medicine changes decided at the three-month visit.",
          "author": "The Human Record generator",
          "created": "2026-11-04T21:00:00-05:00"
        },
        "recorded_date": "2026-08-10"
      }
    ],
    "guidelines": [
      {
        "guideline_id": "GL-ADA-2026",
        "title": "Standards of Care in Diabetes—2026",
        "publisher": "American Diabetes Association (Diabetes Care 2026;49(Suppl 1))",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41358886/",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-IWGDF-2023",
        "title": "Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update)",
        "publisher": "International Working Group on the Diabetic Foot (Diabetes Metab Res Rev 2024)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/37243927/",
        "version_or_year": "2023"
      },
      {
        "guideline_id": "GL-IWGDF-PAD-2023",
        "title": "The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes and a foot ulcer",
        "publisher": "IWGDF, European Society for Vascular Surgery, and Society for Vascular Surgery (Diabetes Metab Res Rev 2024)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/37726988/",
        "version_or_year": "2023"
      },
      {
        "guideline_id": "GL-ACC-PAD-2024",
        "title": "2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease",
        "publisher": "American College of Cardiology and American Heart Association (Circulation 2024)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/38743805/",
        "version_or_year": "2024"
      },
      {
        "guideline_id": "GL-AHA-CCD-2023",
        "title": "2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease",
        "publisher": "American Heart Association and American College of Cardiology (Circulation)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/37471501/",
        "version_or_year": "2023"
      },
      {
        "guideline_id": "GL-CMID-2026",
        "title": "CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs",
        "publisher": "Aether Forge",
        "url": "https://patrickrutledge.github.io/topthirty/",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-AWV-CMS",
        "title": "Medicare Wellness Visits (Medicare Learning Network)",
        "publisher": "Centers for Medicare & Medicaid Services",
        "url": "https://www.cms.gov/outreach-and-education/medicare-learning-network-mln/mlnproducts/preventive-services/medicare-wellness-visits.html",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-PREV-2026",
        "title": "Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements",
        "publisher": "Aether Forge",
        "url": "https://patrickrutledge.github.io/preventative_services/",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-USPSTF-DEP-2023",
        "title": "Depression and Suicide Risk in Adults: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/screening-depression-suicide-risk-adults",
        "version_or_year": "2023"
      },
      {
        "guideline_id": "GL-USPSTF-FALLS-2024",
        "title": "Falls Prevention in Community-Dwelling Older Adults: Interventions",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/falls-prevention-community-dwelling-older-adults-interventions",
        "version_or_year": "2024"
      },
      {
        "guideline_id": "GL-USPSTF-BREAST-2024",
        "title": "Breast Cancer: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
        "version_or_year": "2024"
      },
      {
        "guideline_id": "GL-USPSTF-OSTEO-2025",
        "title": "Osteoporosis to Prevent Fractures: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosis-screening",
        "version_or_year": "2025"
      },
      {
        "guideline_id": "GL-USPSTF-CRC-2021",
        "title": "Colorectal Cancer: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
        "version_or_year": "2021"
      },
      {
        "guideline_id": "GL-USPSTF-HCV-2020",
        "title": "Hepatitis C Virus Infection in Adolescents and Adults: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/hepatitis-c-screening",
        "version_or_year": "2020"
      },
      {
        "guideline_id": "GL-USPSTF-ALC-2018",
        "title": "Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/unhealthy-alcohol-use-in-adolescents-and-adults-screening-and-behavioral-counseling-interventions",
        "version_or_year": "2018"
      },
      {
        "guideline_id": "GL-CDC-IMZ-2026",
        "title": "Adult Immunization Schedule by Age",
        "publisher": "Centers for Disease Control and Prevention",
        "url": "https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-STRIDE-2025",
        "title": "Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial",
        "publisher": "The Lancet (Bonaca MP, et al.)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/40169145/",
        "version_or_year": "2025"
      }
    ]
  },
  "review": {
    "schema_validation": {
      "status": "not_started",
      "notes": "Run scripts/build.ps1 -Conformance."
    },
    "clinical_review": {
      "status": "not_started",
      "notes": "Awaiting clinician review; check the hypoglycemia plan (glipizide stopped, glargine reduced and moved to the morning), empagliflozin and semaglutide with peripheral artery disease and retinopathy, low-dose rivaroxaban with aspirin, the decision to defer revascularization during supervised exercise therapy, and the IWGDF risk grading."
    },
    "provenance_review": {
      "status": "not_started",
      "notes": "A 1996 wire obituary, the PBS American Masters timeline, a Newsweek obituary, VOA Learning English, and the official foundation page are logged. Every health claim is from these public reports; the type of diabetes and all modern findings are synthetic."
    },
    "safe_messaging_review": {
      "status": "not_started",
      "notes": "Recent-death rule applies. The 1993 amputations and her death are recorded as history only, in plain sentences; the modern episode does not stage or predict them. No mental-health or substance claim is made."
    }
  }
}
